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The complement and coagulation systems are two interrelated plasma protein cascades. 
Evidence from observational and animal studies has proposed a role for the complement 
system in the development of venous thromboembolism (VTE), but the exact mechanisms 
remain obscure.  
 The aim of this thesis was to investigate whether activation of the complement 
system impacts the risk of VTE and to investigate which pathways may be involved. The 
procoagulant properties of the lectin pathway, in particular, demanded closer inspection. 
Genetic variations associated with plasma levels of complement protein or activation 
products were also explored to discover novel genetic regulators that could potentially 
contribute to thrombosis risk. 
 The fourth survey of the Tromsø Study was used as the parent cohort for all of the 
nested case-control studies discussed in this thesis. There were 462 individuals who 
experienced a VTE in the follow-up period (1994/95-2007). For each VTE case, two age- and 
sex-matched controls who were alive at the index date of the VTE event were randomly 
sampled from the source cohort. 
 The findings in this thesis support a role for the complement system in the 
development of VTE. Higher baseline levels of complement activation as measured by the 
soluble terminal C5b-9 complement complex (TCC) were associated with future risk of VTE, 
as were high levels of plasma mannose-binding lectin (MBL). The rs8176719 SNP of the ABO 
gene, which determines O and non-O blood types and is itself a known risk factor for VTE, 
was found to be significantly associated with high plasma MBL levels. Individuals with high 
plasma MBL levels and type O blood were found to have a similar risk for VTE as individuals 
with non-O blood type, regardless of plasma MBL levels. 
 These studies implicate that the lectin pathway is involved in the mechanisms leading 
to venous thrombosis. Functional studies are warranted. Additionally, the discovery of a 
relationship between blood type and plasma MBL levels requires further investigation, both 
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Venous thromboembolism (VTE) is a term that encompasses two serious conditions that are 
part of the same disease entity: deep vein thrombosis (DVT) and pulmonary embolism (PE). 
Deep vein thrombosis is a condition that occurs when a blood clot forms in the deep veins, 
most commonly in the lower extremities. Signs and symptoms of DVT include pain, redness, 
and swelling in the affected limb due to obstructed blood flow. Pulmonary embolism is a 
potentially life-threatening condition that occurs when a piece of a growing venous blood 
clot breaks off, travels through the bloodstream, and lodges in the narrow vasculature of the 
lungs. Though often assumed to be a sequela of DVT, up to 50% of PE have an untraceable 
origin [1]. It has been proposed that intracardiac thrombus formation as a result of atrial 
fibrillation is a source of up to 20% of PE [2], and other pathological mechanisms of PE may 
include local thrombus formation in the lung vasculature [1]. Symptoms of this serious 
condition include chest pain, tachypnea, dyspnea, and coughing. Severe cases can result in 
circulatory collapse and death.  
VTE is a common disease with an annual incidence of 1-2 per 1000 persons in 
Western Europe [3, 4], but the mechanisms in the pathogenesis of VTE remain elusive. 
Immunothrombosis is thrombus formation as a result of the activation and interplay of 
several intravascular protein cascades: the coagulation, fibrinolytic, complement, and kinin-
kallikrein systems [5].  
Hemostasis is the physiological mechanism by which the body is able to stop bleeding 
at a site of injury. The process of hemostasis is divided into primary hemostasis, or the 
formation of a platelet plug, and secondary hemostasis, or the formation of a fibrin mesh 
that strengthens and stabilizes the plug and forms the resultant clot. Secondary hemostasis 
is a process controlled by the coagulation cascade, an ancient intravascular proteolytic 
cascade that ultimately results in the formation of a fibrin mesh. As the ability to stop 
bleeding is vital to survival, hemostasis must be tightly regulated to ensure effective clotting 
and limit bleeding, and just as importantly, to avoid inappropriate clotting. Thrombosis, or 
the pathological formation of clots in blood vessels in the absence of bleeding, can result 
from dysregulation and excessive activation of the coagulation system. Thrombosis is 
essentially “hemostasis in the wrong place and at the wrong time [6].” 
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At a site of open injury it is critical that the body protects against the introduction of 
foreign pathogens in addition to stopping bleeding. The complement system is an ancient 
protein cascade closely connected to the coagulation cascade. This mainly intravascular 
proteolytic system has a wide range of functions, including: integration of the innate and 
adaptive immune systems by clearing and lysing foreign pathogens, promotion of 
inflammation, contribution to normal development of tissues and organs, and promotion of 
tissue repair [7]. The activation of complement or other components of the intravascular 
innate immune system interact with and amplify each other to drive the 
thromboinflammatory process [8]. 
This thesis explores the role of the complement system in the development of venous 
thrombosis, and aims to unravel the potential role of mannose binding lectin (MBL) and the 
lectin pathway in the pathogenesis of VTE. 
 
1.1. Epidemiology of venous thromboembolism  
VTE is the third most common cardiovascular disease (CVD) following myocardial infarction 
and stroke [9], and is a major cause of morbidity and mortality around the world. The 
incidence of VTE is 1-2 per 1000 person-years [3, 4], and has remained stable [10] or even 
increased in the last 20 years [4, 11], in alarming contrast to the 25-40% decrease in 
incidence of arterial CVD over the same time period [12]. The incidence of VTE (both DVT 
and PE) increases exponentially with age for both sexes [13, 14]. While women have a twice 
higher incidence in childbearing years [13, 15], the incidence rate is higher in men of all ages 
when reproductive risk factors are taken into account [16]. People of different ethnic 
background have differing incidence rates of VTE, with African-American populations having 
the highest risk, especially for PE, and decreasing risk in those of Caucasian, Hispanic, and 
Asian/Pacific Islander descent, respectively [17]. 
 VTE presents as deep vein thrombosis in approximately two-thirds of patients, while 
about one-third of VTE events present as pulmonary embolism [18]. However, this ratio is 
changing, with recent studies showing that the rate of PE has increased approximately 250% 
over the last two decades [4, 11], likely due to more frequent diagnosis by better imaging 
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techniques (e.g. computed tomographic pulmonary angiography) [11]. These studies also 
found that rates of DVT have decreased over the same time period. 
 Despite the improvements in diagnostic methods as well as in treatment of VTE, the 
rate of adverse events remains high. The 30-day case fatality rate for overall VTE was found 
to be between 6.4-10.6%, with 30-day case-fatality rates being roughly twice as high in PE 
patients than in DVT patients. This difference disappeared within one year [13, 19]. Several 
studies have found one-year case fatality rates to be between 21-24% [13, 19, 20], with rates 
significantly higher in cancer-related VTE (as high as 88%)[21]. 
 VTE is a common and chronic disease that recurs in approximately 30% of patients 
within 10 years [14]. The highest risk of recurrence is between 6-12 months after the first 
event [22]. Patients with an initial DVT have a 1.4-fold higher risk of recurrence than those 
with a first PE [20]. Several studies have found that the initial disease usually recurs at the 
same site [20, 23], i.e. DVT tends to recur as DVT and PE recurs most commonly as PE. 
Unprovoked VTE events are more than twice as likely to recur than events provoked by 
transient risk factors [24]. 
 As VTE is a chronic disease, patients can suffer from several long-term complications 
that constitute a major health burden for society. The sequelae of VTE include post-
thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH). 
PTS presents with edema, swelling, chronic pain, and skin changes in the limb affected by 
DVT – severe cases can lead to leg ulceration [25]. Between 20-50% of DVT patients develop 
PTS [15, 25], with 5-10% developing severe PTS [26, 27], due to damage to the venous valves 
and subsequent venous hypertension and impaired venous return. Female sex, obesity, 
proximal DVT, recurrent DVT, and varicose veins are risk factors for PTS [26]. The Villalta 
score, a clinical severity scoring system for PTS, correlates well with both clinical 
measurements and patient-perceived quality of life (QoL) [28]. In addition to increasing 
healthcare costs due treatment and hospitalization, PTS also negatively affects QoL [29, 30]. 
Patients suffering from PTS reported a worse QoL compared to other chronic diseases, 
including angina, chronic lung disease, and osteoarthritis [31]. In a recent cohort of over 
60,000 individuals of working age in the general population, VTE was associated with 
considerable work-related disability, with the risk of work-related disability in subjects with 
VTE being 62% higher when compared to individuals without VTE in a model adjusted for age 
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and sex [32]. Those with unprovoked VTE had a 52-67% higher risk of work-related disability, 
while it is notable that no association was found between provoked VTE and subsequent risk 
of disability [32]. DVT was associated with disability, while PE was not. This is likely 
attributable to the frequency of PTS and the rarity of CTEPH. 
 CTEPH is a rare complication of acute PE, affecting between 2-4% of PE patients [33]. 
Risk factors for CTEPH include young age, unprovoked PE, and recurrent VTE [33, 34]. 
Symptoms of CTEPH include fatigue, dyspnea, and chest discomfort, and in severe cases 
hemoptysis due increased pulmonary hypertension from vascular remodeling after 
thrombus organization [35]. CTEPH is a disease with progressive pulmonary hypertension 
and ultimately right heart failure, if untreated [35]. CTEPH is the most severe form of the 
post-pulmonary embolism syndrome, an increasingly recognized long-term complication of 
PE [36]. Recent studies suggest that post-PE syndrome affects almost half of PE patients, and 
these patients suffer an impaired QoL [37]. Post-PE syndrome manifests as dyspnea and 
exercise intolerance, along with diminished right ventricular function and perfusion defects. 
Currently, however, there are no clear diagnostic criteria for this condition.  
 
1.2. Pathophysiology of venous thromboembolism 
Already in the 1856, Rudolph Virchow proposed that there were three main factors involved 
in thrombus formation, which later became known as Virchow’s Triad (Figure 1)[38]. These 
factors are changes in blood flow (stasis), changes in blood composition (hypercoagulability), 
and vessel wall injury. For over one and a half centuries, these three key elements have 
proven relevant and critical in the understanding of the pathogenesis of venous thrombosis. 
Established risk factors for venous thromboembolism can be classified under at least one 
element in Virchow’s triad [39]. 
           
Figure 1. Virchow’s Triad  
Changes in blood flow (stasis), the 
composition of blood 
(hypercoagulablity), and vessel 
wall injury (endothelial 
dysfunction) were proposed by 
Rudolph Virchow to be important 




 As blood flows in the veins, it follows a low-pressure system back to the right heart. 
To counteract the effects of gravity, skeletal muscle contraction helps compress venous 
vessels, and backward flow is prevented by venous valves. From autopsy and phlebography 
studies, it has been established that the deepest recesses of the venous valves are the site of 
initiation of thrombus formation [40].  
 There are several changes that occur to blood flow in the areas around these valves. 
First, some blood begins vortical flow as it crosses the leaflets of the venous valve. Blood and 
its cellular components become trapped in the deepest recesses of the valvular sinuses 
(Figure 2). In this pocket of stasis, the cells are cut off from a fresh blood supply and a 
hypoxic environment begins to form. Hamer et al. showed that stasis resulted in severe 
hypoxia and low oxygen tension in the deepest recesses of the venous valves in immobilized 
dogs [41]. Indeed, this is the same location that had previously been described as the origin 
of venous thrombi found in human autopsy studies [40, 42]. Stasis in the venous valves is 
also evident from venography studies that observed contrast material lingers for up to an 
hour after the procedure in the elderly [43]. With age, veins lose their compliance and 
venous valves stiffen from fibrosis, causing disrupted blood flow. These physical changes in 
the veins likely contribute to the increased incidence of VTE with increased age [40].  
 
 
 The hypoxic milieu induces several stress responses within the trapped cells and 
affected endothelium. Hypoxia induces the formation of reactive oxygen species (ROS) and 
Figure 2. Venous valvular sinuses 
Deep vein thrombosis has been 
shown to originate in the valvular 
pockets of the deep veins. The 
changes in blood flow due to the 
valves result in vortical flow and 
stasis. The lack of flow creates a 
hypoxic environment which activates 
the endothelium and the trapped 
cellular components, including 
leukocytes. Tissue factor (TF)-bearing 
monocytes (Mc) and extracellular 
vesicles (EVs) as well as activated 
platelets (Plt) are key factors in the 
initiation of thrombus formation. 
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activates oxygen dependent transcription factors hypoxia-inducible factor-1 (HIF-1) and early 
growth response-1 (Egr-1)[40]. These transcription factors upregulate a multitude of genes, 
including those responsible for glycolysis, vasomotor control, and angiogenesis [44]. Of note, 
Egr-1 has been found to upregulate tissue factor (TF) (a key initiator of the coagulation 
system) on monocytes following hypoxia [44]. 
 Hypoxia also activates endothelial cells to express a proinflammatory and 
procoagulant phenotype (Figure 3). Activated endothelium releases Weibel-Palade bodies, 
which contains von Willebrand Factor (vWF) and several adhesion molecules. vWF binds 
platelets and thereby promotes platelet aggregation at the endothelial surface. P-selectin 
from Weibel-Palade bodies is exposed on the surface of the activated endothelium, and 
binds P-selectin glycoprotein ligand-1 (PSGL-1) expressed on circulating leukocytes and 
extracellular vesicles (EVs). The activated endothelium produces plasminogen activator 
inhibitor-1 (PAI-1) to inhibit fibrinolysis. It also produces ROS, which recruits and activates 
monocytes. No gross vessel injury has been found in autopsy studies on non-traumatic DVT 
[42], but activated endothelium represents stress and dysfunction in the lining of vessel 
walls. 
 The proteins and adhesion molecules expressed by activated endothelial cells in 
response to hypoxia (e.g. P-selectin, E-selectin, vWF) capture leukocytes, platelets, and EVs. 
Histological studies that venous thrombi form in alternating layers of red, fibrin-rich layers 
with multiple trapped erythrocytes and white, platelet-rich layers known as the lines of 
Zahn. The layer found immediately on the endothelial surface is fibrin-rich and red, and is 
indicative of TF-induced fibrin formation [40]. TF is expressed mainly on circulating 
monocytes and EVs [45, 46] and activates the extrinsic pathway of coagulation. Indeed, a 
recent study in mice elegantly showed the recruitment of TF-bearing leukocytes to the intact 
but stenotic vessel wall using in vivo microscopy in an inferior vena cava model [47]. The 
procoagulant environment of the venous valvular sinuses thus also represents the 








1.3. Risk factors for venous thromboembolism 
Venous thrombosis is a complex, multicausal disease with many risk factors [48]. These risk 
factors are classifiable by the elements of Virchow’s triad [39, 48], but are usually classified 
as genetic or acquired risk factors. The presence of several risk factors in one individual is 
common, and often required before venous thrombosis manifests. These risk factors interact 
dynamically, and the additive and supra-additive effects of several risk factors is represented 
in the thrombosis potential model (Figure 4)[48]. In this model, VTE manifests when an 
individual’s thrombosis potential exceeds the thrombosis threshold.  
Figure 3. Pathophysiology of venous thromboembolism 
Hypoxia in the venous valvular sinuses activates endothelial cells, which release von Willebrand factor (vWF) 
and adhesion molecules from Weibel-Palade bodies. The Weibel-Palade bodies then bring P-selectin and vWF 
to the endothelial surface, where they bind P-selectin glycoprotein ligand-1 (PSGL-1)-bearing leukocytes and 
extracellular vesicles (EVs) and platelets, respectively. Monocytes and EVs also carry tissue factor (TF) to the 
site, which initiates the clotting cascade and begins the formation of a fibrin-rich clot. 




    
 
1.3.1. Heritable risk factors  
Heritable, or genetic risk factors, are major contributors to the risk of VTE. From family and 
twin studies the heritability of the disease has been estimated to be around 50-60% [49, 50]. 
Thrombophilia is a term indicating an increased genetic predisposition to VTE as a result of 
hypercoagulability [51].  
 Genetic defects in inhibitors of the coagulation pathway, including antithrombin, 
Protein C, and Protein S were among the first thrombophilic disorders identified. In 1965, 
Egeberg discovered that clustering of VTE events in a Norwegian family occurred due to a 
Figure 4. The thrombosis potential model                                                                                  
Individual thrombosis potential is influenced by both genetic and acquired risk factors. These risk factors 
interact dynamically and have an additive or even supra-additive effect. If several factors are present, the 
thrombosis potential may approach or exceed the thrombosis threshold, which leads to development of 
venous thromboembolism (VTE). In this example, the baseline thrombosis potential of the individual is 
elevated due to the presence of the Factor V Leiden mutation (FVL), and increases with age. Provoking factors 
at various time points additionally push the thrombosis potential toward the thrombosis threshold, until finally 
exceeding it, leading to a VTE. A provoking factor early in life may not cross the thrombosis threshold, but with 
increased age the same factor may cross the thrombosis threshold and provoke VTE. 




partial antithrombin deficiency. Though very rare (<1% for all), deficiencies in these natural 
anticoagulants are strong risk factors for VTE, increasing risk 5- to 50-fold [50, 52, 53].  
 There are also several moderate genetic risk factors for VTE. Factor V Leiden (FVL) is a 
mutation in coagulation factor V. The prevalence of this mutation among Europeans is about 
5%, and it gives a 2-4-fold increased risk of DVT [54, 55]. This mutation affects the activated 
Protein C (APC) cleavage site on Factor V, thus causing resistance to APC anticoagulation 
[55]. Interestingly, FVL seems to have a differential effect on DVT and PE, known as the “FVL 
paradox”, giving an OR of 4.5 for DVT and OR 1.7 for PE [56, 57].  
 Prothrombin G20210A is the second most common inherited thrombophilia and 
occurs in about 2% of Caucasians [58]. It is another moderate risk factor for DVT, increasing 
the risk roughly 3-fold [59]. The prothrombin G20210A mutation is a gain-of-function 
mutation, giving 30% increased levels of prothrombin. The mutation also inhibits fibrinolysis 
through a thrombin-activatable fibrinolysis inhibitor (TAFI)-mediated mechanism, further 
contributing to thrombosis risk [60].  
 Although the risk of VTE conferred by non-O blood types is less than that of FVL or 
prothrombin G20210A, due to its high frequency in the population (60-70%), non-O blood 
type is the commonest genetic risk factor [61] with a population attributable risk of 20% 
[62]. Compared to type O blood group, B and A1 blood groups have a relative risk of about 2 
for venous thrombosis [54, 63, 64]. ABO blood group determines plasma levels of vWF and 
FVIII. Plasma vWF levels are 25% higher in non-O individuals compared to those with type O 
[65]. Increased levels of vWF and FVIII are also known risk factors for VTE, even after 
adjusting for ABO blood group [66]. However, increased vWF/FVIII levels only account for 
part of the increased thrombotic risk, and the risk remains elevated for non-O blood groups 
even after accounting for vWF and FVIII [67, 68]. 
 The fibrinogen gamma gene (FGG) encodes the fibrinogen γ chain. The γA chain is the 
main variant, but an alternatively spliced γ´ version also occurs. Patients with VTE were 
found to have reduced γA/γ´ fibrinogen levels and reduced γ´ fibrinogen/total fibrinogen 
ratios [54, 69]. Decreased γ´ fibrinogen levels in the FGG-H2 haplotype give an approximately 
1.45-fold increased risk of VTE [69]. Studies suggest that the γ´ fibrinogen chains contain 
binding sites for FXIII and thrombin that ultimately inhibit thrombin [69]. Fibrin clots formed 
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from γA/γ´ fibrinogen contain finer chains and more extensive cross-linking than γA/γA 
fibrinogen [70]. These changes along with the observed resistance to fibrinolysis likely 
contribute to the increased risk of thrombus formation in individuals with low γ´ fibrinogen 
levels [69]. 
 Many genetic factors for VTE have been discovered since the 1990s. Genome wide 
association studies (GWAS) have identified several single nucleotide polymorphisms (SNPs) 
associated with VTE [50, 71]. As of 2015, 17 VTE-associated genes have been discovered 
[50]. Some of these new SNPs are novel and surprising, as they do not belong to the known 
coagulation pathways nor have they been previously associated with other CVD [72, 73]. 
These SNPs provide new areas to investigate in the pathophysiology of VTE. De Haan et al. 
proposed a genetic risk score using SNPs in the criteria for a risk prediction model for VTE 
[74]. Risk scores incorporating risk alleles of 31 SNPs performed similarly to a model 
incorporating five SNPs most strongly associated with VTE. The model was further improved 
by combining genetic and non-genetic risk factors [74]. Discoveries based on whole exome 
and whole genome sequencing studies hold promise in determining novel risk prediction 
models in the future [50]. 
 
1.3.2. Acquired risk factors 
There are several acquired risk factors for VTE. Some of these environmental factors are 
considered provoking factors, and can be transient or persistent risk factors [75].  
 Age is one of the strongest risk factors for VTE. The incidence of VTE increases 
exponentially with age [13, 14], with the risk of VTE being 50- to 80-fold higher in the elderly 
[76]. Studies have suggested that between 78% [76] and 90% [77] of the population 
attributable risk of VTE is due to age. Blood becomes more hypercoagulable with age, due to 
an increase in procoagulant factors without a concomitant increase in natural anticoagulants 
[78, 79]. Additionally, body mass index (BMI) increases with age [80], while activity 
decreases and immobilization increases due to illness, infection, and co-morbidity [81]. 
Fibrotic changes that stiffen the venous valves predispose to stasis, while inactivity and loss 
of muscle mass also contribute to reduced venous return and stasis in the lower extremities. 
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 Obesity, or a body mass index above 30 kg/m2, is an important modifiable risk factor 
for venous thrombosis. The risk of VTE increases linearly with BMI [82], and obese 
individuals have a 2 to 3-fold higher risk of VTE compared to persons of normal BMI [3, 83]. 
Obesity was found to account for 33% of incident unprovoked VTE [10]. Weight gain has also 
been described as increasing the risk for VTE [84]. Waist circumference has been proposed 
as a better anthropomorphic measure of obesity as it is associated with the highest risk of 
VTE, and identifies the most people at risk [85]. Visceral adipose tissue found in abdominal 
obesity is metabolically active and releases a plethora of proinflammatory and procoagulant 
substances [86, 87]. Though the exact mechanisms  are unknown, it is likely that raised 
intraabdominal pressure and reduced venous return may play a role in thrombogenesis in 
the obese. Recent Mendelian randomization studies have found that there is a causal 
relationship between BMI and VTE [88-90]. 
 Cancer is a major provoking risk factor for VTE, increasing the risk between 4- and 7-
fold [91]. It is estimated that 20-30% of VTEs are associated with cancer [91], and in many 
cases VTE is often the first manifestation of cancer. Indeed, up to 10% of patients are 
diagnosed with cancer within a year after an unprovoked thrombotic event [92]. The risk of 
VTE varies according to the type of cancer, with hematological, lung, brain, gastrointestinal 
tract, and pancreatic cancers having the highest incidence of VTE [93]. Malignancy often 
produces a hypercoagulable state, due to the expression of TF by cancer cells and release of 
procoagulant TF-bearing EVs into the bloodstream [94]. Inflammation and leukocytosis, and 
possibly the presence of neutrophil extracellular traps (NETs) also likely contribute to the 
procoagulant environment bestowed by cancer. Apart from the cancer itself, hospitalization 
and treatment regimens including surgery, chemotherapy, and the use of central venous 
catheters also increase the risk of VTE in cancer patients [95, 96]. Prothrombotic genotypes 
also influence the risk of VTE in cancer, and individuals with FVL, prothrombin G20210A and 
non-O blood types have increased risks of cancer-related VTE [97]. These risks were often 
supra-additive. To illustrate, it was found FVL mutation gave a 3-fold higher risk of VTE, 
cancer gave a 5-fold risk, and FVL and cancer together gave a 12-fold increased risk [97, 98].  
 Major general surgery is also an established provoking factor for VTE, giving up to 22-
fold increased risk [95, 99]. The highest risk surgeries were major orthopedic surgery, 
neurosurgery, and major vascular surgery [100]. The increased risk for VTE is a result of the 
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inflammatory response and hypercoagulable state that develops during the postoperative 
period [101-103]. Trauma is also an important risk factor, giving an over 12-fold increased 
risk [95]. It is estimated that without thromboprophylaxis up to about 58% of trauma 
patients may suffer from DVT [104].   
 Acute medical conditions are also independent risk factors for VTE. Arterial 
cardiovascular disease including myocardial infarction (MI) [105, 106] and ischemic stroke 
[106, 107] are associated with increased risk of VTE in the general population, especially 
during the first few months following an acute cardiovascular event. The risk of VTE was 
almost five-fold higher in subjects having suffered an MI compared to subjects without MI 
during the first 6 months after diagnosis of MI [105]. Moreover, it was found that over 72% 
VTE events were attributable to an MI, while almost 79% of PE were attributable to MI [105]. 
Ischemic stroke was associated with a 3-fold higher risk of VTE compared to individuals 
without stroke, with the greatest risk being 20-fold higher in the first month after stroke 
[107]. Several diseases that have a longer course are also associated with an increased risk of 
VTE. Congestive heart failure [108] reflects a condition in which all components of Virchow’s 
triad are fulfilled, thereby conferring an increased risk for both DVT and PE [109]. Lung 
disease including chronic obstructive pulmonary disease (COPD) [110] or respiratory failure 
[93] and rheumatologic disorders [111] such as systemic lupus erythematosus are also risk 
factors for VTE.  
 Immobilization is another recognized risk factor for VTE, conferring a 2- to 5-fold 
increased risk of VTE [112, 113]. There is a bidirectional relationship between immobilization 
and infection, with infection causing bed-rest and immobilization, and immobilization 
predisposing to infections such as pneumonia [114]. A recent case-crossover study in the 
general population found that immobilization led to an OR of 72.5 for VTE, and this risk 
almost doubled when infection was also present [115]. Infection is also a known risk factor 
for both DVT and PE [116].  
 Pregnancy and oral contraceptives are also risk factors for VTE. Among the many 
changes with pregnancy is a transient hypercoagulable state due to increased coagulation 
factors FVII, FVIII, FX, fibrinogen, vWF and PAI-1 [117, 118]. Compared to women who are 
not pregnant, pregnant women have a 4- to 5-fold increased risk for VTE, while the risk 
during the postpartum period is 20-fold increased [117, 119]. For women taking oral 
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contraceptives, the risk for VTE is transiently increased (in the first year) about 2- to 4-fold 
[120]. In individuals with FVL mutation who were taking hormonal contraceptives the risk 
increased to 36-fold [120], showing the strong synergistic effect of multiple risk factors on 
overall thrombotic risk. 
 
1.4. The coagulation system 
The coagulation system is a proteolytic cascade that culminates in the formation of fibrin 
and the activation of platelets, which form the blood clot. The coagulation system is 
comprised of two pathways: the extrinsic/tissue factor pathway and the intrinsic pathway. 
These two pathways merge into one common pathway to form thrombin, which cleaves 
fibrinogen to give fibrin (Figure 5). While the extrinsic pathway is involved in normal 
hemostasis, it is believed that both pathways contribute to pathological thrombosis [121]. 
 The extrinsic pathway is also known as the tissue factor (TF) pathway. TF is an 
integral membrane protein expressed by extravascular cells, including pericytes, vascular 
smooth muscle cells, and adventitial fibroblasts within the walls of blood vessels [45]. It is 
also expressed by monocytes under pathological conditions. TF serves a critical role in 
hemostasis, underscored by the fact that a deficiency in humans has never been discovered, 
and murine studies have shown that TF-deficiency is incompatible with life [45]. 
Extravascular TF is exposed upon vascular injury and binds circulating coagulation factor 
(F)VII and the miniscule amount (~1%) of circulating activated FVII(a) with high affinity [122]. 
Upon complexing with TF, the inactive zymogen FVII is rapidly converted to FVIIa. Negatively 
charged phospholipids such as phosphatidylserine (PS) are a prerequisite for FIX and FX 
binding to cell surfaces as well as the decryption of TF, which expresses binding sites of the 
TF:FVIIa complex for its substrates [121, 123]. The TF:FVIIa complex then activates its 
substrates FIX and FX to FIXa and FXa, respectively [124]. Small amounts of thrombin are 
formed as a result, which then activates cofactors FV and FVIII. The clotting cascade then 
continues to propagate when FIXa and FXa assemble on appropriate membrane surfaces 
together with their respective cofactors (FVIIIa and FVa, respectively). Binding of these 
coagulation factors to PS on activated platelets or damaged cells immensely enhances the 
reaction rate of proteolytic conversion of zymogens to active serine proteases, thereby 
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amplifying the reaction [125]. Indeed, in the absence of appropriate lipid membranes, most 
coagulation enzymes show little activity with their substrate in a biologically relevant time 
frame. The prothrombinase complex, FXa and cofactor FVa, activates prothrombin to 
thrombin. Thrombin is another key component of the coagulation cascade, and has key roles 
in amplification of the clotting cascade and platelet activation. With formation of large 
amounts of thrombin, fibrinogen is cleaved to fibrin monomers. These fibrin monomers 
polymerize spontaneously and FXIIIa, also activated by thrombin, cross-links fibrin chains to 
stabilize the clot [126].          
  The intrinsic pathway of the coagulation cascade is activated in the absence of TF. It 
is triggered upon contact of plasma factor XII with a number of negatively charged artificial 
surfaces. There are also several proposed activators in vivo, such as platelet-derived 
polyphosphates [127] and extracellular nucleic acids [128, 129]. Contact with an activator 
results in a conformational change in FXII that produces small amounts of FXIIa. A positive 
feedback loop starts when FXIIa activates prekallikrein (PK) to kallikrein, which activates FXII 
in a reciprocal manner. FXIIa further activates FXI to FXIa. FXIa converts FIX to FIXa, which 
forms the tenase complex with its cofactor FVIIIa [130]. This activates FX to FXa in the final 
common pathway of coagulation to produce thrombin and finally, fibrin. Interestingly, the 
intrinsic pathway does not seem to contribute significantly to hemostasis in vivo. Unlike TF, 
FXII is not “essential” to life, and neither mice nor humans who are deficient for FXII have 
defects in hemostasis [131]. Several studies have implicated a role for FXII and the intrinsic 
pathway in thrombosis [132, 133], and have proposed both FXII and FXI as potential 
therapeutic targets [134]. 
 The coagulation cascade should be considered in context of the cell-based model of 
hemostasis. In this model, there are three key phases of hemostasis: initiation of coagulation 
by TF-bearing cells, amplification on platelet surfaces, and propagation on activated platelets 
[135]. Fibroblasts, pericytes, activated endothelial cells, and monocytes are the main cells 
that express TF. Extracellular vesicles (EVs), a term encompassing exosomes and 
microvesicles/microparticles, are membranous structures 30-1000 nm in diameter derived 
from cells. Exosomes are vesicles secreted from the cell, while microvesicles (formerly called 
microparticles) bud off from the membrane of cells. EVs are found in biological fluids and 
have been linked to important physiological and pathological processes. These include the 
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elimination of waste products as well as intercellular communication and signaling through 
exchange of nucleic acids, lipids, and proteins expressed on or carried in EVs [136]. The 
surface markers, proteins, and nucleic acids expressed by EVs are derived from the parent 
cells, and thus EVs are heterogeneous and have varied biological activity [137]. EVs are an 
important source of TF as well as negatively charged phospholipids such as PS, and are thus 
highly procoagulant [128].  
 Upon vessel wall injury, TF-expressing extravascular cells bind FVII in plasma, forming 
the TF:FVIIa complex and initiating the extrinsic pathway of the coagulation cascade. The 
small amount of thrombin produced activates platelets, which adhere to the site of injury 
and set the stage for the amplification of coagulation by binding cofactors FVa and FVIIIa to 
their surfaces. The tenase (FVIIIa/IXa) and prothrombinase (FXa/FVa) complexes then 
assemble on platelet surfaces and produce large amounts of thrombin in the propagation 
phase. Thrombin converts fibrinogen to fibrin, forming a fibrin clot.  
 Coagulation must be kept tightly regulated, as excessive clotting is harmful to the 
host. Tissue factor pathway inhibitor (TFPI) directly inhibits FXa and thus inhibits the 
prothrombinase (FXa/FVa) complex. It also inhibits the TF:FVIIa complex mostly through 
feedback inhibition [138]. The importance of TFPI is underscored by the finding that mice 
deficient in TFPI die in utero and humans deficient for TFPI have never been reported, 
strongly suggesting that TFPI deficiency is incompatible with life [139]. Another important 
natural anticoagulant is antithrombin, which primarily inhibits FXa and thrombin of the 
common pathway, as well as the TF:FVIIa complex in the presence of heparin [140]. Protein 
C is another natural anticoagulant. Activated protein C (APC) inactivates FVa and FVIIIa  
when bound to its cofactor protein S [141]. As discussed previously, antithrombin, protein C, 





1.5. The complement system 
The complement system is an ancient network of over 50 proteins with pleiotropic functions 
in innate immunity, a first line defense against pathogens. It also plays an important role in 
development and organogenesis, the clearance of tissue debris, apoptotic cells and immune 
complexes, and the promotion of tissue repair following injury, and is thus critically 
important to the preservation of homeostasis [7]. Traditionally, it has been viewed as a 
blood-based system, but recent research points to there being an intracellular system as well 
[142]. There are three pathways with distinct triggers that converge at complement 
component 3 (C3): the classical, lectin, and alternative pathways (Figure 6). Complement 
also has key roles in communication between innate and adaptive immunity by substantially 
Figure 5. A simplified overview of the coagulation system 
The extrinsic pathway is activated by tissue-factor (TF)-bearing monocytes, extracellular vesicles (EVs), and 
possibly activated endothelial cells. The intrinsic pathway is activated in vivo by polyphosphates released from 
platelets or invading bacteria as well as extracellular nucleic acids. These pathways converge at the common 
pathway to form thrombin, and ultimately, fibrin. 










potentiating the antibody [7, 143]. It is not surprising, therefore, that dysfunction of the 
complement system can transform it into a pathological effector rather than one of 
homeostasis. Indeed, complement has been found to be involved in a number of immune, 
inflammatory, and other diseases [144].  
 The classical pathway is initiated by activation of the pattern recognition molecule 
(PRM) C1q. C1q recognizes antibodies (the Fc portion of IgM and IgG clusters) as well as 
pentraxins (such as C-reactive protein) and distinct structures on microbial and apoptotic 
cells [145, 146]. C1r and C1s are subsequently activated upon C1q binding to a recognized 
pattern [146]. C1s thereby cleaves C4 into C4a and C4b. C4a has been found to act as an 
untethered ligand for protease-activated receptors (PAR)1 and PAR4, and thereby activates 
the endothelium [7]. C4b binds covalently to surfaces near the activation sites in a process 
called opsonization. C2 binds to C4b and is cleaved by C1s to C2a and C2b [147]. Thus, C1s is 
involved in the generation of the C3 convertase (C4b2b), which cleaves C3 and initiates the 
common complement pathway. Complement effector functions are produced from this 
point and downstream. 
 The lectin pathway is initiated in a similar way to the classical pathway. Mannose-
binding lectin (MBL)[148], ficolins, and collectins are PRMs that bind to specific carbohydrate 
patterns found on microbes and damaged host cells. Upon binding to an appropriate surface 
pattern, the PRM activates MBL-associated serine proteases (MASPs) to which the PRMs are 
in complex with [149]. MASP-2 cleaves both C4 and C2, and is thus capable of generating C3 
convertase [8] and initiating the common complement pathway.     
 The alternative pathway of complement is activated by spontaneous hydrolysis of a 
small fraction of C3 molecules in a ‘tick-over’ mechanism for constant surveillance [150]. This 
hydrolysis exposes new binding sites on C3H2O, to which factor B (FB) can bind. Factor D (FD) 
then cleaves FB to Bb and Ba, generating the C3 convertase of the alternative pathway 
C3(H2O)Bb. C3b produced by the C3 convertases of the other pathways can also bind FB, 
forming C3 convertase C3bBb [146]. Like the C3 convertases of the classical and lectin 
pathways, these C3 convertases cleave C3 to C3a and C3b. The C3b molecule contains a 
temporary thioester moiety which tags foreign cells by reacting with carbohydrates on 
foreign microbes but not host cells. Properdin (factor P) can associate with and stabilize 
C3bBb convertase by forming the C3bBbP complex, which slows its deactivation [151]. The 
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alternative pathway has an important role in the amplification loop in complement 
activation. Amplification through the alternative pathway makes up to 80-90% of total 
complement activation and thereby produces the majority of C3b and C5b-9 regardless of 
the initiating pathway [152, 153].  
 Regardless of initiation pathway, generation of C3 convertases leads continuation of 
the common pathway as well as amplification of the alternative pathway [154]. The 
anaphylatoxins C3a and C5a are produced in the common pathway and have important 
effects in proinflammatory signaling and phagocytosis [155]. The anaphylatoxins are potent 
chemoattractants that lead neutrophils and monocytes to the site of complement activation 
and promote phagocytosis. Activation of the common pathway of complement culminates in 
the formation of the terminal complement complex (TCC) C5b-9. The TCC forms when C5b 
associates with C6, C7 and this lipophilic complex inserts into a cell membrane, after which it 
associates with C8 and then binds multiple C9 units. When TCC assembles on a membrane 
surface it is called the membrane attack complex (MAC). Sublytic C5b-9 does not lyse cells, 
but form small pores that induce proinflammatory responses via calcium influx [156]. When 
complement activation occurs in the fluid phase, TCC forms in a soluble form (sC5b-9). While 
sC5b-9 still has no known biological function [157], it is measurable in plasma and as such is 
an invaluable tool to monitor complement activation [158].  
 Like the coagulation system, the complement system must be tightly regulated to 
avoid pathological activation. Complement regulators exist in both soluble and cell-bound 
form. C1-esterase inhibitor (C1-INH) inhibits several proteases in the classical (C1r and C1s) 
and lectin pathways (MASP-1 and -2)[159], as well as the coagulation and fibrinolytic cascade 
[160], thus it is not a specific complement inhibitor. sMAP and MAP-1 are splice products of 
the MASP2 and MASP1 genes and are competitive inhibitors of MASPs as they bind to MBL 
and ficolins [8, 161]. Factor H (FH) is the main inhibitor of the C3 convertase of the 
alternative pathway [162]. Factor I cleaves C4b and C3b to give inactivated products (e.g. 
iC3b, C3c, and C3dg) that are unable to assemble into C3 convertases [163]. C4b-binding 
protein (C4BP) is a soluble regulator that binds to C4b and thereby inhibits the classical and 
lectin pathways [164]. Finally, regulators of the convertases accelerate their enzymatic decay 
and include CR1 (CD35), decay accelerating factor (DAF/CD55), and membrane cofactor 
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protein (MCP/CD46). CD59 is a cell-based regulator that prevents formation of sublytic and 




1.5.1. The lectin pathway of complement 
The lectin pathway is the most recently discovered pathway of the three activation pathways 
of the complement system. PRMs of the lectin pathway (e.g. MBL, ficolin-1, ficolin-2, ficolin-
3, and collectin-10, collectin-11, and collectin-12) bind to carbohydrate patterns on 
pathogenic microorganisms and apoptotic cells. These PRMs are specific to steric and spatial 
organization of carbohydrates, thus preventing the erroneous recognition of healthy self-
cells [166]. MBL, ficolins, and collectins circulate in complex with MASPs, which mediate 
Figure 6. A simplified overview of the complement system 
The complement system is comprised of three activation pathways: the classical, lectin, and alternative 
pathways. These pathways converge at complement factor C3. The final common pathway produces 
several important effector molecules, including anaphylatoxins, opsonins, and the terminal complement 
complex (TCC), which can be either soluble (s)C5b-9 or the membrane attack complex (MAC). 






complement activation through generation of the C3 convertase upon binding of the PRM 
on a carbohydrate surface.  
 MASP-1 autoactivates upon PRM binding, and in turn activates MASP-2 [167] to 
cleave C4 and C2 to form the C4b2a convertase [8]. MASP-1 is also able to cleave C2, but not 
C4. Complexes can cross-activate MASPs in nearby complexes [149]. Though the function of 
MASP-3 has remained obscure after its discovery, recent evidence suggests MASP-3 may be 
involved in alternative pathway activation as it can cleave Factor D [168]. There are also two 
non-catalytic, alternatively spliced products of the MASP1 and MASP2 genes, MAP-1 and 
sMAP, respectively [8]. Although most MASPs are associated with PRMs of the lectin 
pathway, some MASPs circulate unbound as well [169]. In addition to cleaving complement 
components, MASP-1 and -2 have been shown to have loose substrate-binding specificities 
that overlap with thrombin, therefore giving these proteins a role in coagulation. MASP-1 is 
an especially promiscuous protein, shown to cleave fibrinogen, FXIII, and prothrombin [170]. 
It also activates TAFI and inhibits fibrinolysis. In plasma systems, MASP-1 promoted the 
formation of a loose clot with thick fibrin fibers in a thrombin-dependent manner [171]. 
MASP-2 has also been shown to cleave prothrombin to thrombin [172]. The procoagulant 
activity of the lectin pathway is discussed in more detail later. 
 
1.5.2. Mannose-binding lectin 
Mannose-binding lectin (also called mannan-binding lectin) was the first pattern recognition 
molecule discovered in the lectin pathway. It is a calcium-dependent C-type lectin that 
recognizes carbohydrate moieties such as mannose and N-acetyl-D-glucosamine on 
membranes of pathogens and damaged or apoptotic host cells. MBL initiates the lectin 
pathway of complement.  
 The MBL2 gene is found on chromosome 10q11.2-21. Plasma MBL levels vary greatly 
and are largely determined by polymorphisms of the MBL2 gene. There are four exons 
within the protein-encoding region of MBL2, and base substitutions in exon 1 at codon 52, 
54, or 57 cause changes to amino acids resulting in lowered plasma MBL levels and 
decreased function [169]. Individuals of the same genotype can have MBL levels that differ 
10-fold [173]. Protein expression of MBL is also dependent on polymorphisms of the 
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promoter region of the gene, thus leading to a wide range of plasma levels of MBL in 
individuals even of the same haplotype [174]. An alternative promoter region 1kb upstream 
of exon 1 of MBL2 has been suggested to affect MBL expression as well, albeit to a much 
smaller degree (up to 15%) [175]. Though these polymorphisms account for most of the 
interracial variation in MBL concentrations, there is still a significant and yet unexplained 
variation in circulating MBL levels [169]. Therefore, it is likely that there are additional 
epigenetic or hormonal factors that affect plasma MBL levels [169].  
 Although there is a great degree of inter-individual variation in plasma MBL levels, an 
individual’s MBL levels in plasma are quite stable throughout life [176]. Age and diurnal 
variation do not appear to affect MBL levels, nor do moderate exercise [177] or weight loss 
[178].  
 It is estimated that between 5 and 20% of the population is “MBL-deficient” with 
levels below 100 ng/mL, though the cut-off level is disputed due to high rates of haplotype 
variation [179-181]. MBL-deficiency has been associated with several diseases, including a 
number of infectious diseases, autoimmune disorders and CVD [176, 182, 183]. Infants and 
children with MBL-deficiency were found to have defects in opsonization and suffer from 
frequent infections [176]. Low MBL levels have been shown to be associated with 
rheumatoid arthritis, systemic lupus erythematosus (SLE), and celiac disease, and in general 
predict a poor prognosis [176].  
  
1.6. Crosstalk between the coagulation and complement systems 
Dysregulation of complement can lead to several clinical disorders, including atypical 
hemolytic-uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). aHUS 
is most commonly caused by either genetic mutations in or autoantibodies produced against 
Factor H, a key regulator of the C3 convertase of the alternative pathway. This results in 
chronic and excessive complement activation. Patients with aHUS suffer from hemolytic 
anemia, thrombocytopenia, and acute renal failure [184]. PNH is caused by a mutation 
affecting glycosylphosphatidylinositol anchors on complement regulatory proteins CD55 and 
CD59, leading to decreased expression of these proteins on cell membranes. This results in 
excessive complement activation. Intravascular hemolytic anemia and red urine are the main 
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signs of PNH. Both disorders are also characterized by thrombosis, manifesting as 
thrombotic microangiopathy in aHUS and as thromboembolism in PNH, highlighting the 
interaction between complement and coagulation [184].  
 Indeed, the recently described concepts of immunothrombosis [5] and 
thromboinflammation [8] reflect the idea that thrombus formation is the result of the 
activation and crosstalk between coagulation and components of the immune system. The 
coagulation and complement systems are linked at several points. 
 The coagulation system has been found to interact with the complement system. 
Thrombin was found to cleave C5 to biologically active C5a and C5b independently of C3 and 
the C3 convertase [185, 186]. (This has recently been challenged by our group (unpublished 
data) since the experiments were done in purified, non-physiological conditions.) 
Additionally FXa, plasmin, thrombin, FIXa, and FXIa were able to cleave both C3 and C5 to 
produce functional anaphylatoxins in a descending order of enzymatic activity for C3 
cleavage [187]. A fragment of FXIIa can activate the classical pathway [188].  
 In parallel, the complement system has several procoagulant effects. C5a induces TF 
expression on endothelial cells [189]. The anaphylatoxins induce platelet activation and 
aggregation [190], through which C3b can bind to P-selectin and assemble the C3 convertase 
[191]. Sublytic concentrations of C5b-9 also activate platelets and expose procoagulant lipids 
such as PS on the surface of platelets and endothelial cells that are necessary for the 
assembly of the prothrombinase complex [192, 193]. Sublytic C5b-9 complexes also induce 
the expression of adhesion molecules on endothelial cells and platelets, and induce the 
secretion of vWF and proinflammatory cytokines. Platelet-derived EVs expressing CD55, 
CD59, clusterin, P-selectin and MAC are also released from activated platelets [194]. 
 Another interesting area of coagulation-complement crosstalk is through vWF. Ultra 
large multimeric strings of vWF released from Weibel-Palade bodies in activated endothelial 
cells function as a binding surface for C3b, thereby promoting assembly of the C3 and C5 
convertases of the alternative pathway [195]. Plasma vWF also binds C3b, but acts as a 
cofactor for C3b cleavage by factor I, thus degrading C3b to inactive iC3b and inhibiting 
complement activation [196]. 
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 The MASPs represent another important bridge between complement and 
coagulation (Figure 7). MASP-1 is a rather promiscuous protease, activating prothrombin 
[171], TAFI, fibrinogen, and FXIII [185]. MASP-1 not only has thrombin-like activity in cleaving 
FXIII and fibrinogen, it can also activate endothelial cells through PAR4 [197]. MASP-2 is also 
able to cleave prothrombin [172]. Both MASP-1 and -2 are efficiently inhibited by 
antithrombin in the presence of heparin [198] and α2-macroglobulin [199], though the 
physiological role of α2-macroglobulin on MASP inhibition has been questioned [200]. 
Although MASPs have procoagulant effects, they are less efficient in cleaving prothrombin 
[172, 201], fibrinogen [201, 202], and FXIII [201] than the native coagulation factors (FXa and 
thrombin, respectively) and therefore their biological role in coagulation are likely 
supplementary rather than redundant [169]. This supporting role is confirmed by a study 
showing that MASP-1 is unable to initiate the clotting cascade [171], but plays a role in 
amplification processes. Another study showed both MASP-1 and -2 are activated by 
activated platelets and fibrin formation in vitro and in vivo, and thereby likely contribute to 
the amplification of thrombosis [203].  
 
Figure 7. Crosstalk between MASPs and the coagulation system 
MBL-associated serine protease (MASP)-1 and -2 cleave prothrombin. MASP-1 has thrombin-like activity and 
cleaves FXIII, TAFI, and fibrinogen. MASP-1 also activates PAR4 on endothelial cells. 
(Adapted from Garred P. A Journey through the lectin pathway of complement- MBL and beyond. 




1.7. Complement and the risk of venous thromboembolism 
Few studies have investigated the role of complement in the development of venous 
thromboembolism. Given the extensive crosstalk between the complement and coagulation 
systems, as well as the role of complement in arterial CVD, it stands to reason that 
complement activation also plays a role in the development of VTE. 
 Complement factor deposition on platelets has been investigated as a potential 
player in the pathogenesis of VTE [204]. Systemic lupus erythematosus (SLE) patients with a 
history of VTE were found to have increased deposition of C1q, C3d, and C4d on platelets 
compared to SLE patients without VTE. The researchers concluded that classical pathway 
activation may be involved in the pathogenesis of VTE in SLE patients.  
Previously only two studies have investigated the effects of MBL on risk of VTE. A 
longitudinal study on MBL2 genotypes in SLE patients showed that although MBL alleles 
conferring deficient phenotypes had an increased risk for arterial thrombosis compared to 
those with normal alleles, there was no association between genotype and risk for VTE 
[205].  In a cross-sectional study on SLE patients, Font and colleagues found that individuals 
with MBL2 genotypes giving low plasma MBL levels had an increased risk of VTE events than 
those with genotypes giving clinically normal MBL levels [206].  
 These studies have implicated the involvement of complement in thrombogenesis, 
but the mechanisms remain elusive. More research is needed to clarify the role of 
complement activation in the development of VTE, including determining which pathways 
are involved in clot formation. Additionally, the association between MBL and risk of VTE 
needs to be investigated in the general population. New insights into the pathological 
mechanisms of the disease are paramount in the improvement and development of novel 







2. Aims of the thesis 
 
The aims of the thesis were: 
 
x To investigate whether complement activation, as measured by plasma levels 
of the terminal complement complex (TCC), is associated with future risk of 




x To investigate whether low plasma mannose-binding lectin (MBL) levels are 
associated with risk of venous thromboembolism (VTE) in a population–based 
nested case-control study (Paper II). 
 
 
x To investigate whether high plasma levels of MBL were associated with 
genetic variants that could influence the association between plasma MBL 










3.1. Study populations 
3.1.1. The Tromsø Study  
The Tromsø Study is a single center, population-based cohort with repeated health surveys 
of the inhabitants of the municipality of Tromsø in northern Norway. In total, seven surveys 
have been conducted, the first in 1974, and most recently, the seventh in 2015/16. The 
primary aim of the cohort was originally to investigate the causes of the unusually high 
cardiovascular mortality in the region and to find ways to prevent arterial CVD such as 
myocardial infarction (MI) and stroke [207]. The cohort has since been invaluable in 
investigating a broader range of chronic diseases and conditions. 
 The fourth survey of the Tromsø Study (Tromsø 4) was conducted in 1994/95. All 
inhabitants 25 years old or older living in the municipality of Tromsø were invited to 
participate in the survey. Of those, 27,158 (77%) participated in the study and were followed 
from date of inclusion (1994/95) until migration from the region, death, or end of follow-up 
(September 1, 2007). Baseline information was collected through self-administered 
questionnaires, blood sampling, and physical examinations in all surveys of the Tromsø 
Study. The questionnaires assessed the participant’s health and lifestyle habits and provided 
information about dietary habits, smoking and alcohol consumption, physical activity, use of 
oral contraceptives or hormone replacement therapy, and diseases such as CVD and 
diabetes. Trained personnel conducted physical examinations on the participants. Height 
and weight measurements were taken in subjects wearing light clothing and no shoes. Body 
mass index (BMI) was calculated by weight in kilograms (kg) divided by height in meters (m) 
squared (kg/m2). Blood samples were drawn from an antecubital vein in a non-fasting state 
and were analyzed in the Department of Clinical Chemistry at the University Hospital of 
North Norway (UNN). Blood cell counts were assessed from blood collected in 5mL 
vacutainer tubes (Becton Dickinson, Meylan Cedex, France) containing the anticoagulant 
EDTA (K3-EDTA 40µL, 0.37mol/L per tube) and were analyzed by an automated blood cell 
counter (Coulter Counter®, Coulter Electronics, Luton, UK) within 12 hours. DNA samples 




3.1.2. Outcome measurements and validation  
Participants in Tromsø 4 were followed from date of inclusion (1994/95) until VTE event, 
migration from the region, death, or the end of the study period (September 1, 2007). As 
UNN is the only hospital that serves the municipality of Tromsø, it provides all hospital-based 
and outpatient medical care in the region, including diagnosis and treatment of VTE. All VTE 
events during follow-up were identified using the following registries at UNN: the hospital 
discharge registry, the radiological procedure registry, and the autopsy registry. 
International Classification of Diseases, revision 9 (ICD-9) codes 325, 415.1, 452, 453, 671.3, 
671.4, and 671.9 were used to identify VTE events that occurred between 1994 and 1998, 
while revision 10 (ICD-10) codes I26, I80, I82, I67.6, O22.3, O22.5, O87.1, O87.3 were used 
for the period 1998 until 2007. After identification of events, trained personnel who were 
blinded to the baseline variables of the patients reviewed medical records for every 
potential case of VTE for validation. VTE cases from the hospital discharge registry and 
radiological procedure registry were recorded if all of the following criteria were fulfilled:  
1) Clinical signs or symptoms of a DVT or PE, or both, were present  
2) the VTE event was objectively confirmed by an objective diagnostic procedure 
(i.e. compression ultrasound, venography, computed tomography (CT), perfusion-
ventilation scan (VQ-scan), pulmonary angiography, or autopsy) 
3) a physician noted the diagnosis of DVT or PE in the patient’s medical record 
4) the patient was given therapy for VTE (i.e. anticoagulant medication, 
thrombolysis, vascular surgery) unless specifically contraindicated  
VTE cases from the autopsy registry were recorded if VTE was indicated as the cause 
of death or was noted as a significant condition contributing to death in the autopsy report.  
 VTE events were classified as either a DVT or PE. If both DVT and PE were present, 
the event was recorded as a PE. Each VTE event was further classified as provoked or 
unprovoked according to the presence or absence of factors provoking VTE at the time of 
diagnosis. An event was classified as provoked if at least one of the following were present: 
active cancer, trauma or surgery within the previous eight weeks, acute medical conditions 
(major infection, acute MI, or stroke), immobilization (bedrest > three hours, wheelchair use, 
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or long-haul travel > four hours in the last two weeks prior to the event), or any other factor 
specifically described in medical records to be provoking. 
 
3.1.3. Study design 
A nested case-control study conducted with participants from Tromsø 4 (1994/95-2007) was 
used in all papers in this thesis. During the follow-up period, 462 individuals experienced a 
VTE event. Two age- and sex-matched controls who were alive at the index date were 
randomly sampled from the source cohort for each VTE case (n=924). A number of 
individuals (47 cases and 76 controls) did not have plasma of sufficient quality for laboratory 
measurements of TCC and were therefore excluded. In Paper I, the final study included 415 
VTE cases and 848 controls. The aim was to investigate the association between plasma 
levels of TCC and future risk of incident VTE.  
 In Paper II, we used the same nested case-control study from Tromsø 4. A total of 45 
cases and 75 controls did not have plasma samples of sufficient quality for laboratory 
analysis of MBL levels. The study therefore included 417 VTE cases and 849 age- and sex-
matched controls, all of whom were followed until the date of adjudicated VTE event, 
migration, death, or end of follow-up. The aim of the study was to investigate whether there 
was an association between plasma MBL levels and future risk of VTE.  
 In Paper III, we used the same nested case-control study as in papers I and II. Plasma 
samples were of insufficient quality in 45 cases and 75 controls, and were therefore 
excluded from this study. This study included 417 VTE cases and 849 controls. Additionally, 
whole exome sequencing was only available in a subgroup of this population (355 VTE 
patients and 354 controls). We conducted a protein quantitative trait loci (pQTL) analysis 
using whole exome sequencing data to find potential genetic variants that are associated 
with high MBL levels (highest quartile from our previous study in paper II).  
  
3.2. Laboratory measurements 
Non-fasting blood was drawn into 5mL vacutainer tubes (Becton Dickinson, Meylan Cedex, 
France) containing the anticoagulant EDTA (K3-EDTA 40µL, 0.37mol/L per tube) in the 
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Tromsø 4 study. Platelet-poor plasma was then prepared by centrifugation at 3000xg for 10 
minutes at room temperature, and the supernatant was then transferred into cryovials 
(Greiner Laboratechnik, Nürtringen, Germany) in 1mL aliquots and stored at -80°C until 
further analysis. In all analyses, platelet-poor plasma samples were thawed in a water bath 
at 37°C for 5 minutes and then centrifuged at 13000xg for 2 minutes to obtain platelet-free 
plasma.  
In Paper I, plasma TCC levels were measured using an in-house enzyme-linked 
immunosorbent assay (ELISA) as described in detail previously [208]. ELISA plates (Nunc, 
Immunoplate II, Copenhagen, Denmark) were coated with monoclonal antibody aE11 
specific for a neoantigen exposed in the poly-C9 unit after formation and incorporation into 
the TCC. Biotinylated anti-C6 monoclonal antibody (9C4) was used as the detection antibody 
and streptavidin horseradish peroxidase (GE Healthcare UK) was added in the final step. The 
optical density was measured at 405 nm (Dynatech MR580, Dynatech Laboratories Inc., 
Alexandria, VA, USA). Results are presented in Complement Arbitrary Units (CAU)/mL. The 
intra-assay coefficient of variation was negligible, and the inter-assay coefficient of variation 
was 10.3%. The limit of detection was 0.3 CAU/mL. 
In Paper II and III, plasma levels of MBL were measured using an enzyme-linked 
immunosorbent assay (Bioporto Diagnostics A/S, Hellerup, Denmark) according to the 
manufacturer’s instructions. Briefly, samples were brought to room temperature and 100 µL 
of diluted plasma were added to each microwell pre-coated with monoclonal antibody 
against MBL and allowed to incubate for 60 minutes on a shaking platform. After addition of 
100 µL biotinylated MBL antibody and incubation under shaking for 60 minutes, the wells 
were washed. 100 µL HRP-conjugated streptavidin was added to each well and allowed to 
incubate for 60 minutes on the shaking platform before washing. Finally, 100 µL 
chromogenic substrate (TMB) was added to each well and allowed to develop for 15 minutes 
in the dark before the reaction was stopped chemically and the plates were read at 450 nm 
in a plate reader. The intra-assay coefficient of variation is between 3.8-5.5%. The limit of 
detection was 5 pg/mL. 
 In all papers in this thesis, plasma levels of CRP were measured using an in-house 
enzyme-linked immunosorbent assay (CRP antibody: DY1707, R&D). Briefly, samples were 
brought to room temperature and pipetted in duplicates using a SELMA pipetting robot 
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(Jena, Germany) and a BioTek dispenser/washer (EL406, Winooski, USA). Commercially 
available reagents were used for enzyme-immunoassay (R&D Systems, USA) in a 384 format. 
An EIA plate reader (Synergy H1 Hybrid, BioTek, USA) was used with absorption at 450 nm 
and wavelength corrected to 540 nm. The intra- and inter-individual coefficients of variation 
were 2.6% and 9.1%, respectively. The limit of detection was 0.1 mg/mL. 
   In Paper III, we used the same measurements for MBL and CRP as in paper I. In 
addition, genotyping of DNA for the non-O vs. O blood group SNP (rs8176719) was 
performed using the Sequenom platform. Molecular mass of the extended primers were 
measured by single-base extension followed by mass spectrometry. DNA (10-20 ng) isolated 
from whole blood was genotyped with the Sequenom iPlex Gold Assay according to the 
recommended protocol and analyzed by the MassARRAY Analyzer 4. Only genotypes with a 
high quality score (A. conservative or B. moderate) were used. Non-O blood type was 
assigned to individuals with 1 or 2 alleles for the rs8176719 SNP, and type O was assigned to 
individuals with no alleles. Whole exome sequencing at high-coverage (≈100x) was 
performed in a subgroup of the nested case-control study (355 VTE patients and 354 
controls) using the Agilent SureSelect 50 Mb capture kit.  
 
3.3. Statistical analyses 
All statistical analyses were conducted using STATA version 15 (StataCorp LLC, Texas, USA) or 
R version 3.4.4 (The R Foundation for Statistical Computing c/o Institute for Statistics and 
Mathematics, Wien, Austria).  
In Paper I, plasma TCC levels were categorized according to quartile cut-offs in the 
control population (<0.80, 0.80-1.04, 1.04-1.40, >1.40 CAU/mL). Descriptive statistics were 
used to calculate means and proportions of baseline characteristics. Logistic regression 
models were used to estimate odds ratios (OR) of VTE with 95% confidence intervals (CI) 
according to quartiles of TCC levels. The lowest quartile of TCC was used as the reference 
group. The p-value for linear trend was calculated across increasing quartiles of TCC, as well 
as the OR per 1 standard deviation (SD) increase in TCC. 
In Paper II, plasma MBL levels were categorized according to quartile cut-offs in the 
control population (<435, 435-1367, 1367-2422, >2423 ng/mL). Descriptive statistics were 
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used to calculate the means and proportions of baseline characteristics across quartiles of 
MBL levels. Logistic regression models were used to calculate ORs of VTE and subgroups with 
95% CI across quartiles of MBL, using the highest quartile of MBL as the reference group. We 
also calculated the p-value for linear trend in VTE risk across decreasing quartiles of MBL. 
 In Paper III, plasma MBL levels were categorized into quartile cut-offs in the control 
population (<435, 435-1367, 1367-2422, >2423 ng/mL). The lower three quartiles (Q1-3) 
were then merged to produce two groups for analysis: participants with low (merged 
quartiles Q1-3) and high (Q4) MBL levels. Descriptive statistics were used for calculation of 
means and proportions of baseline characteristics in the low and high MBL groups.  
 The pQTL analysis of whole exome sequencing data including 1,034,910 genetic 
variants. The commonly used significance threshold of 5x10-8 was used to adjust for multiple 
testing. Plasma MBL levels were divided into low and high categories (outcomes), with the 
lower three quartiles defined as the low MBL category and the highest quartile making up 
the high MBL category. The pQTL analysis was performed using EPACTS (Efficient and 
Parallelizable Association Container Toolbox) software edition 3.3.0 (University of Michigan, 
2016). Within EPACTS, we used the logistic regression Wald test adjusted for age, sex, BMI, 
and VTE status to test for associations between high and low MBL levels (outcome) and 
allele counts of different genetic variants modelled as a linear variable. 
 Logistic regression models were used to estimate ORs with 95% CI for VTE according 
to blood groups (type O blood group and non-O blood group). Finally, ORs with 95% CI for 
VTE and subgroups were estimated using logistic regression for combinations of MBL and 
blood groups (low/high MBL and O/non-O blood group) using the low MBL / O blood group 
as the reference group. Sensitivity testing was also conducted to eliminate the possibility 
that co-morbidities that may be triggers for VTE influenced our findings. MI, stroke, 
infection, or cancer that occurred within 3 months prior to VTE event were excluded from 





4. Main results  
4.1. Paper I  
 
Complement activation assessed by the plasma terminal complement complex and future 
risk of venous thromboembolism 
Observational and animal studies have suggested that components of the complement 
system (e.g. C3 and C5) are involved in the pathogenesis of venous thromboembolism (VTE). 
However, it remains unknown whether there is an association between plasma levels of the 
terminal complement complex (TCC) and future risk of incident VTE.  
 We aimed to investigate whether plasma TCC levels were associated with risk of 
incident VTE in a nested-case control study and to explore whether there were any genetic 
variants associated with plasma TCC using protein quantitative trait loci (pQTL) analysis of 
exome sequencing data.  
 Plasma TCC levels from 415 subjects with VTE and 848 age- and sex-matched controls 
from the population-based cohort (the Tromsø Study) were measured using ELISA. Whole 
exome sequencing using the Agilent SureSelect 50Mb capture kit was performed on 709 
individuals (355 VTE patients and 354 controls). Logistic regression models were used to 
estimate odds ratios (OR) with 95% confidence intervals (CI) across quartiles of plasma TCC 
levels.  
 The risk of VTE increased across quartiles of plasma TCC, especially for unprovoked 
VTE (p for trend 0.02). Individuals with plasma TCC levels in the highest quartile (>1.40 
CAU/mL) had an OR 1.33 (95% CI: 0.96-1.86) for overall VTE and OR 1.72 (95% CI: 1.08-2.75) 
for unprovoked VTE compared to individuals with plasma TCC levels in the lowest quartile 
(<0.80 CAU/mL) in a logistic regression model which adjusted for age, sex, and body mass 
index. The OR for VTE increased with shortened time between blood sampling and VTE 
event. There was no significant association between genome-wide or complement-related 
gene variants and plasma TCC levels. Our findings imply that plasma TCC levels are 
independent of gene regulation and that high plasma TCC levels are associated with risk of 




4.2. Paper II  
 
Plasma Levels of Mannose-Binding Lectin and Future Risk of Venous Thromboembolism 
Mannose-binding lectin (MBL) is a C-type lectin that binds to repetitive carbohydrate 
patterns such as mannose on damaged host cells. The binding of MBL to such repetitive 
patterns activates the lectin pathway of the complement system. Individuals who are 
clinically deficient in MBL (<100ng/mL) have a high prevalence of associated diseases, 
including various types of infectious diseases, autoimmune diseases, and arterial 
cardiovascular disease.  
 We aimed to investigate the association between plasma levels of MBL and risk of 
VTE. We conducted a nested case-control study derived from the general population (the 
Tromsø Study), with 417 VTE cases and 849 age- and sex-matched controls who were alive at 
the index date of the VTE event. Plasma MBL levels were measured using ELISA. Logistic 
regression models were used to estimate odds ratios (OR) and 95% confidence intervals (CI) 
for VTE across quartiles of plasma MBL levels.  
 Individuals with plasma MBL levels in the lowest quartile (<435 ng/mL) had a 
decreased OR for overall VTE (OR 0.79, 95% CI: 0.56-1.10) and deep vein thrombosis (DVT) 
(OR 0.70, 95% CI: 0.47-1.04) compared to individuals with plasma MBL levels in the highest 
quartile (>2423 ng/mL) after adjusting for age, sex, body mass index, and C-reactive protein 
in the regression model. The ORs decreased substantially with decreasing time between 
blood sampling and VTE event for VTE, DVT, and pulmonary embolism (PE).  
 Our findings suggest that low plasma levels of MBL are associated with a reduced risk 








4.3. Paper III 
 
ABO Status Affects Plasma Mannose-Binding Lectin Levels and the Association Between 
MBL Levels and Risk of Venous Thromboembolism 
The lectin pathway of the complement system is a potentially procoagulant pathway. Our 
aims in this study were therefore to investigate whether high plasma MBL levels were 
associated with any genetic variations that could influence the association between plasma 
MBL levels and risk for VTE.  
 We performed a nested case-control study with 417 VTE patients and 849 age- and 
sex-matched controls from a population-based parent cohort (The Tromsø Study). Plasma 
MBL levels were measured using ELISA. Whole exome sequencing was performed using the 
Agilent SureSelect 50Mb capture kit on 709 subjects (355 VTE patients and 354 controls) and 
the data was used in a protein quantitative trait loci (pQTL) analysis. Logistic regression 
models were used to estimate odds ratios (OR) and 95% confidence intervals (CI) for VTE and 
subgroups across groups combining MBL levels and ABO blood groups.  
 The pQTL analysis found that the rs8176719 SNP of the ABO gene, which 
differentiates between type O and non-O blood groups, was significantly associated with 
high plasma MBL levels. Mean plasma MBL levels were 40% higher in individuals with non-O 
blood type than in individuals with type O blood (1842±1614 ng/mL vs 1318±977 ng/mL, 
respectively, p=2.8x10-8). Individuals with type O blood and high plasma MBL levels had 
increased ORs for VTE, DVT, and PE compared to individuals with low MBL levels in the same 
blood group. High MBL levels did not have an additional impact VTE risk in individuals with 
non-O blood type. 
 Our findings suggest that ABO blood group is partly responsible for determining 
plasma MBL levels, and individuals with high plasma MBL levels and type O blood have 
increased risk for VTE, with ORs of similar magnitude to individuals with non-O blood types. 
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5. General discussion 
5.1. Methodological considerations 
5.1.1. Study design 
All the papers in this thesis used data derived from the Tromsø Study, a population-based 
cohort study. A cohort study follows a defined population from inclusion until the outcome 
of interest [209]. In the studies in this work, participants in The Tromsø Study were followed 
until VTE or death, migration from the municipality, withdrawal from the study, or end of the 
study period. Exposure status was recorded at inclusion in the study. Blood samples were 
also taken at inclusion in the study. Relative risk for VTE, the probability of developing DVT 
or PE, when comparing different groups with different exposures can be estimated using the 
cohort study design. The prospective nature of these studies makes them useful in studies 
investigating risk factors or the natural history of a given disease [210]. Other strengths of 
cohort studies are large participant pools and long follow-up times. Additionally, the cohort 
design allows for determination of both absolute risk and relative risk. The clear temporal 
relationship between exposure and outcome is a strength of cohort studies, and the most 
important prerequisite for causality. Hill’s guidelines suggest other criteria that should also 
be considered for causality, including experimental evidence, the strength of the association, 
dose-response, biologic plausibility, and consistency across studies [211]. Challenges with 
the cohort study design include selection bias, confounders, and bias due to differential loss 
to follow-up, which will be discussed in the next section [209]. 
 Case-control studies have a retrospective design, where a group with the outcome of 
interest is compared with a group without the outcome. The exposure information is 
acquired for both groups, and an odds ratio is estimated for the proportion of cases with the 
exposure compared to the proportion of controls with the same exposure. This study design 
is cost-efficient because the known outcome requires a smaller sample size. However, case-
control studies are subject to selection bias, recall bias, and confounding (discussed in 
following sections) [209]. Another potential problem with case-control studies is reverse 
causality. Reverse causality is a type of temporal bias that occurs when the observed 
association is the opposite of the hypothesized causal relationship (i.e. the outcome of 
interest causes changes in the exposure of interest) [211].  
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 Papers I-III utilize a nested case-control study design. Nested case-control studies are 
case-control studies carried out within a cohort, and thereby share features and advantages 
of both cohort and case-control studies [211]. All participants in this type of study (cases and 
controls) are derived from the parent cohort. In our studies, two age- and sex- matched 
controls alive at the index date of VTE event were sampled from the parent cohort for each 
VTE case to reduce confounding and to ensure that there were no losses to follow-up. The 
nested case-control study design was chosen for our investigations primarily because it is 
efficient with regards to time and costs, and the prospective temporal sequence between 
the exposure and outcome of the parent cohort study is preserved. Additionally, the random 
sampling of two matched controls from the source population that the cases were derived 
from increases the likelihood that our controls are representative of the general population. 
Moreover, there is better control for confounding [209, 211]. In our studies, we used logistic 
regression models and adjusted for known confounders to estimate ORs for VTE and 
subgroups by plasma levels of TCC or MBL. 
 
5.1.2. Bias 
A systematic error in the design of a study resulting in incorrect estimates of a true 
association between exposure and outcome is termed bias. Bias is commonly classified as 
selection bias or information bias. 
 Selection bias is a result of systematic errors in the recruitment or retention of 
participants in a study [211]. Cohort studies are less likely to be affected by selection bias, as 
all participants (both cases and controls) are included in the study before the outcome of 
interest occurs. Despite this, cohort studies may be prone to a particular type of selection 
bias called non-response bias (also known as participation bias), where participants differ 
from non-participants [212]. Individuals who choose to participate in cohort studies may be 
healthier and more health conscious than non-attendees. Individuals who are 
institutionalized or immobilized due to illness or disease are unlikely to attend health 
surveys. In general, those who do not participate in an epidemiological study are more likely 
to be men, unmarried, at extremes of age (younger, older), have less education, and be of 
lower socioeconomic status than those who choose to participate [212]. Tromsø 4 recruited 
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77% of the eligible population (all individuals in the general population aged 25 and older) 
[207]. Indeed, it has been found that subjects who did not attend the Tromsø Study tended 
to be <35 years old or >80 years old, single, and have a higher proportion of men than 
attendees [207].  
 In all papers in this work, controls were randomly sampled and matched with cases 
on age and sex to minimize potential differences in the exposure groups. The average age of 
individuals suffering a VTE event in these three papers was 67 years old, which is similar to 
the average of VTE found in other cohort studies in Scandinavian populations [213]. There 
were an equal proportion of men and women experiencing VTE in all papers, as has been 
previously established by other studies [213] . Finally, the proportions of DVT and PE (62% 
and 38%, respectively) were comparable to previous studies [18]. The cases in our nested-
case control studies are therefore representative of individuals with VTE in the general 
population, giving them a high external validity. Controls were randomly sampled from the 
same parent cohort (Tromsø 4), and matched to cases on age and sex, as well as time in the 
study. 
 The generalizability of a study is the extent to which the results can be applied to a 
defined population. This is also known as the external validity of a study [214]. Tromsø 4 had 
a 77% participation rate among those eligible [207]. The participants included a higher 
proportion of women and individuals between the ages of 35 and 80 years than in the non-
participant group [207], and the generalizability is therefore decreased in individuals 
belonging to subgroups representing non-attendees (i.e. men, <35 and >80 years old). 
Inhabitants of Tromsø municipality are predominantly Caucasian, with a Sami minority. The 
homogeneity of the study population thus likely makes it comparable to other Caucasian 
populations. It is less clear whether findings in the Tromsø Study are generalizable to 
different ethnic populations, as the incidence of VTE [17] and the gene polymorphisms for 
the MBL2 [215, 216] and ABO [217] genes differ between ethnicities.  
 The internal validity of a study is the extent to which the observed results reflects the 
true association in the population observed. Randomized control trials are the gold standard 
of study design to minimize effects of bias and confounding and maximizing internal validity. 
Despite this, the strict inclusion and exclusion criteria also limits the external validity of these 
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studies [209]. The high participation rate (77%) of our population-based cohort study 
increases its external validity. 
 In paper I, a similar proportion of cases and controls (47 (10%) and 76 (8%), 
respectively) did not have plasma samples of sufficient quality to analyze for TCC levels. 
Similarly, in papers II and III, 45 (10%) cases and 75 (8%) controls lacked plasma of sufficient 
quality for analysis of MBL. These individuals were excluded from the studies. The 
proportion of missing data was low in both groups and most likely non-differential (as 
sample quality does not depend on the outcome), thereby allowing for exclusion of these 
individuals without a major loss of statistical power. Any measurement error that may have 
occurred under analysis of plasma samples is likely to be a random error rather than a 
systematic error as it occurs by chance. 
        Another type of selection bias that may affect cohort studies is loss to follow-up 
[218]. This occurs when there is a difference in the probability of completing the study 
between the exposure groups. However, as the study designs in this thesis are nested case-
control studies within the source cohort, all controls were alive when the corresponding case 
occurred and all participants were alive through follow-up.  
 Information bias occurs as a result of the systematic tendency to erroneously place 
participants in different exposure/outcome categories. This leads to misclassification of 
exposure and/or outcome. There are several biases that may result in misclassification, 
including: detection bias, observer/interview bias, recall bias, and reporting bias [218]. In our 
studies, observer/interview bias was minimized as measurements used in our analyses were 
taken by trained personnel. Body measurements to calculate body mass index and blood 
samples used to measure TCC, MBL, and CRP were collected by trained personnel. VTE 
events were well-validated by objective criteria, thereby limiting misclassification. Random 
errors in laboratory measurements may also result in misclassification. Other baseline 
variables were collected through self-administered questionnaires. While this method is 
cost-effective and efficient, it is prone to reporting bias. Participants may fear judgement 
about socially undesirable behaviors such as drinking or smoking and thus underreport their 
usage [218]. Participants may also refuse to answer questions they find sensitive or 
embarrassing. As questionnaires were filled out at inclusion in the study before the 
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thrombotic event occurred, there is no risk of recall bias, where individuals who experienced 
an event are more likely to remember an exposure than those who did not. 
 Misclassification can be non-differential or differential [218]. Differential 
misclassification bias occurs when the degree of misclassification of the exposure or the 
outcome is different between the groups being compared. It can occur when the 
misclassification of the exposure is dependent on the outcome, for example if the sensitivity 
of identifying an exposure in cases is higher than in controls [211]. Similarly, it can occur 
when the outcome is related to the exposure, for example if a disease is more frequently 
detected due to an exposure, and true cases in the unexposed group remain undetected and 
thereby misclassified [219]. Differential misclassification may lead to bias toward or away 
from the null. For example, recall bias is a classic example of differential exposure 
misclassification as cases are more likely to remember relevant exposures compared to 
individuals who did not suffer the outcome of interest. Non-differential misclassification 
bias occurs when the misclassification is the same across comparison groups for all 
participants and can be due to misclassification of exposure or outcome status. When the 
variable of interest is binary, the estimate is biased towards the null and the association is 
underestimated, but if there are more than two exposure categories, bias away from the null 
is also possible [211]. The end-point evaluating committee was blinded to the baseline risk of 
the participants in the Tromsø Study to avoid potential differential misclassification due to 
knowledge of exposure status affecting diagnosis probability. Any misclassification that may 
have occurred was therefore likely non-differential, as it was likely to be similar between the 
cases and controls. Non- differential misclassification is common in cohort studies, and can 
result from measurement errors or incomplete self-administered questionnaires. Special 
care must be taken on wording of questionnaires to avoid misunderstanding and minimize 
potential misclassification.  
 Regression dilution bias is a type of information bias that affects longitudinal studies 
assessing the relationship between baseline measurements of a continuous variable and an 
outcome. Regression dilution bias is an example of non-differential misclassification. It is 
caused by random measurement errors, either due to technical errors due to imprecise 
measurement devices or biological variation [220, 221]. In the nested case-control studies 
used in this thesis, the participants were followed for up to 12 years. In paper I, the variable 
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of interest (TCC) was subject to variation over the long follow-up period, making our results 
prone to underestimation of the real association between exposure (TCC) and outcome 
(VTE) [222]. In papers II and III, variation in MBL levels during the follow-up period could lead 
to lower than the true risk estimates. We therefore performed sensitivity analysis by 
restricting the maximum time from blood sampling in Tromsø 4 to the VTE events while 
keeping all the controls in the analysis. Logistic regression analysis on time restriction was 
set to require a minimum of 10 VTE events, and ORs were estimated at every 0.1 year 
increase in time since blood sampling and plotted as a function of maximum time. In paper I, 
the risk of VTE by plasma levels of TCC declined substantially with time between blood 
sampling and event. Paper II showed that the ORs for VTE, DVT, and particularly PE by low 
MBL levels decreased with shortened time between blood sampling and the respective 
events. In paper III, ORs for PE by high plasma MBL levels were higher with shortened time 
between blood sampling and event. These sensitivity analyses show that all our results were 
affected by regression dilution bias to some extent, giving us attenuated OR estimates. 
 
5.1.3. Confounding and mediation 
A confounder is a variable that is associated with both the exposure and the outcome but is 
not in the causal pathway [211]. This leads to confounding, or mixing of effects. A 
confounder distorts the association between exposure and outcome. There are different 
approaches to correct for the presence of confounding, including stratification, matching, 
and regression models [223]. Regression is the most common method to minimize 
confounding in observational studies [209]. Multivariable analysis allows for the 
demonstration of an independent association between a variable of interest and an 
outcome after adjusting for potential confounding factors [224]. By using regression analysis 
models rather than stratification to correct for confounding, the statistical power of the 
study remains the same as data from all participants is used [211].  
 As previously discussed, age is a strong risk factor for VTE [13, 14]. Obesity is another 
major risk factor for VTE, accounting for 33% of unprovoked incident VTE [10]. While the risk 
is higher in females of childbearing age compared to men of similar age [15, 225], the overall 
age-adjusted incidence rate is higher for men than for women [14]. Age, sex, and BMI are 
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associated with risk of VTE, but their association with MBL levels is less clear. Immune 
system function is known to decline with age. Whether this also applies to the complement 
system remains unknown [226, 227], though one study found that classical and alternative 
pathway functional activity was enhanced with age, and terminal complement components 
(C5, C8, and C9) increased with age [226]. Interestingly, concentrations of complement 
activation products analyzed did not differ between age groups stratified by decade 
(between 20-70 years old) [226]. The same study found females have significantly lower 
median serum MBL concentrations compared to men, but no significant differences between 
the sexes were found in overall lectin pathway activity [226]. In our nested case-control 
study in Paper II and III, there was no correlation between MBL levels and age, and females 
had a significantly lower mean MBL level than men (1317 ng/mL vs 1463 ng/mL, p=0.03). 
Though neither we nor others have found that MBL levels differ in individuals with normal 
BMI and obesity [228], we included BMI as a covariate, along with age and sex, in our 
regression models to exclude the possibility that these factors were confounding the 
apparent association we found between plasma MBL levels and risk of VTE. 
 C-reactive protein (CRP) is an acute phase protein, with levels increasing during the 
inflammatory response [229]. Several studies have found that CRP levels are associated with 
increased risk of VTE [230-232]. MBL and CRP are both acute phase proteins, and activators 
of complement pathways [233]. Nevertheless, CRP has been found to have additional effects 
on MBL-mediated complement activation, both enhancing the lectin pathway or inhibiting 
MBL-mediated cytolysis through the inhibition of the alternative pathway [233]. In papers II 
and III, CRP was included as a covariate in our multivariable models for VTE. Nevertheless, 
comparing estimated ORs to a logistic regression model without CRP as a covariate suggests 
that CRP had little effect and did not act as a confounder in our studies.  
 A phenomenon that closely resembles confounding is mediation. Like a confounder, a 
mediator is an additional variable associated with a predictor of interest and the outcome. 
However, a mediator must be a causal consequence of the predictor of interest [234]. In 
papers II and III, we did sensitivity analysis to remove the possibility that MBL levels may 
predispose to any co-morbidities that are established triggers for VTE. These mediators 
include myocardial infarction [105], stroke [107], acute infection [115], and cancer [91] 
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occurring within 3 months of a VTE event. In these studies, we excluded participants with 
any of these conditions from our analysis to remove their potentially mediating effects.  
 It is important to consider that despite careful consideration in selection of covariates 
for multivariable analysis, the possibility that our studies may be affected by residual 
confounding remains. Residual confounding occurs when unrecognized confounders exist 
that are excluded from multivariable analysis or the categories of the confounder adjusted 
for are too broad and thereby result in imperfect adjustment [211]. Thus the associations we 
found in our studies could potentially be a result of unrecognized confounding variables that 
were not taken into account. Residual confounding is a common threat to large 
observational studies. 
 
5.1.4. Missing data 
Missing data is common and may introduce bias into an epidemiological study. Missing data 
can be a result of failure to respond to certain questions in a questionnaire, loss to follow-
up, equipment failure, incorrect handling or loss of samples for laboratory measurements, 
and many other reasons [235]. It is thus imperative that studies are carefully planned and 
executed to minimize data loss. There are several solutions, but no optimal approach, to 
handling missing data. These include omission of variables with missing values, omission of 
individuals with incomplete data, or imputation (estimation) of missing values [235]. If a 
large proportion of data is omitted to account for missing data, statistical power may be 
reduced as a result.  
 In the papers in this thesis, plasma samples with insufficient quality were excluded 
from the studies. As the proportion of missing data was low in both case and control groups 
(10% and 8%, respectively) and likely non-differential, we could exclude these individuals 
without a major loss of statistical power.  
 In all papers in this work, other binary variables denoting basic characteristics such as 
smoking and CVD that contained missing values were treated as not having that trait. For 
example, if an individual’s information about smoking was missing, he or she was classified 
as a non-smoker. This data was missing from very few individuals (2 (0.2%) individuals for 
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smoking, 3 (0.2%) for CVD, 5 (0.4%) for CRP, 3 (0.2%) for BMI, and 4 (0.3%) for diabetes), and 
























5.2. Discussion of the main results 
5.2.1. Complement activation and risk of venous thromboembolism (Paper I) 
In Paper I, we investigated whether activation of the complement system, measured by 
plasma levels of the soluble terminal complement complex (TCC), was associated with risk of 
venous thromboembolism. In this population-based nested case-control study, we found 
plasma TCC levels in the highest quartile were associated with a 74% higher risk of 
unprovoked VTE compared to the lowest quartile. No genetic variants across the whole 
genome or the complement-related genome were significantly associated with TCC levels. 
 This study was the first to investigate the association between plasma TCC levels as a 
reflection of overall complement activation in vivo and risk of VTE. Prior to this study, there 
have been few studies investigating the role of the complement system in the development 
of VTE. In a large, prospective study in the general population in Copenhagen, Nørgaard and 
colleagues reported that participants with plasma C3 levels in the highest tertile had a 58% 
higher risk for VTE compared to those in the lowest tertile [236]. The risk estimate was 
attenuated after adjustment for CRP and BMI, but remained 31% elevated compared to the 
lowest tertile. The authors speculated that C3 and complement activation is likely a mediator 
in the pathogenesis of venous thrombosis, although they could not exclude the possibility 
that C3 was a bystander and merely functioned as a marker of inflammation in a similar 
manner to CRP. 
 Subramaniam et al. used an inferior vena cava ligation model in mice to induce DVT 
and study the contributions of complement factors to platelet activation and fibrin 
formation [237]. They showed that C3-deficient mice had a reduced incidence of thrombus 
formation and size compared to wild-type mice. Additionally, platelet activation was 
diminished, and deposition of platelets and fibrin were also reduced compared to control 
animals. C5-deficient mice also had reduced thrombus size. This study implicated 
complement as a mediator of thrombus formation.    
 In Paper I, we assessed in vivo complement activation by measuring soluble TCC 
levels. The TCC, or the membrane attack complex (MAC) if assembled on a membrane 
surface, is the final activation product of complement activation. It is composed of C5b, C6, 
C7, C8, and multiple C9s (C5b-9), forming a pore-like structure that aids in cell lysis. While 
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studies suggest that TCC is biologically inert, it has proven a useful tool for measuring 
complement activation [157]. TCC has been investigated as a procoagulant molecule in 
several in vitro studies. Sublytic C5b-9 was found to increase PS expression on platelets and 
to increase FVa and Xa binding to the plasma membrane, culminating in increased platelet 
prothrombinase activity [238, 239]. C5b-9 also induces TF expression in endothelial cells 
[240, 241] as well as secretion of vWF from Weibel-Palade bodies [242]. Indeed, C5b-9 has 
also been associated with arterial CVD [243]. Our study shows for the first time that TCC is 
also associated with VTE.  
 The lack of genetic variants associated with TCC levels shows the importance of 
environmental factors in complement activation. As complement activation is a tightly 
controlled process, there need to be clear initiating mechanisms. Triggers for activation 
include hypoxia, and it has been shown that the classical pathway is activated upon hypoxia-
reoxygenation of human umbilical vein endothelial cells [244, 245]. Human endothelial 
oxidative stress also activates complement via MBL and the lectin pathway [246]. Venous 
thrombi develop in the venous valvular sinuses [40, 42], areas of severe local hypoxia [41]. 
Local endothelial cells are subjected to oxidative stress under these hypoxic conditions, likely 
increasing binding of MBL and thereby lectin pathway activation as in experimental settings. 
While MBL does not usually bind to host cells, it has been shown to bind to apoptotic cells 
[247, 248]. Hypoxia results in changes in cell protein expression and glycosylation [249] of 
endothelial cells, which may explain MBL recognition of altered self-cells. The lectin pathway 
therefore deserved to be investigated as a prothrombotic pathway in the development of 
VTE, and was used in the studies performed in Paper II and III. 
  There remain several important points to consider in our study. Sensitivity analysis 
restricting time from blood sampling to VTE event shows that the associations we found 
were affected by regression dilution bias due to the long follow-up period. Therefore, the 
ORs for the true association for risk of VTE are underestimated. Overall, the implications of 
our study are in agreement with the findings of other studies investigating complement and 
venous thrombosis, though our results need to be externally validated. The mechanisms 
initiating complement activation remain undiscovered, and future functional studies will be 




5.2.2. Plasma mannose-binding lectin levels and risk of venous thromboembolism (Paper II) 
In paper II, we examined whether plasma levels of mannose-binding lectin were associated 
with risk of venous thromboembolism in a nested case-control study derived from a 
population-based cohort study (The Tromsø Study). Individuals in the lowest quartile of 
plasma levels of MBL had a reduced OR for VTE (OR 0.79, 95%CI: 0.56-1.10) and DVT (OR 
0.70, 95%CI: 0.47-1.04) compared to individuals with MBL levels in the highest quartile after 
adjusting for age, sex, BMI, and CRP. 
Studies that have examined the association between MBL levels and the risk of VTE 
are sparse. Two of these studies were done on SLE patients using MBL genotyping rather 
than plasma MBL measurements, and their results were discordant, with one group having 
found that MBL2-deficient genotypes had an increased risk of VTE in a cross-sectional study 
[206], while no association with risk of VTE was found in a prospective cohort [205]. The 
discrepant results could be due to different study design, different variant alleles that were 
analyzed in the two studies, or a difference in outcome prevalence in the different study 
populations. Additionally, as plasma MBL levels vary up to 1000-fold among healthy 
individuals [250], and more than 10-fold even among those of the same haplotype [173], the 
results of these studies will likely have yielded different results if they had measured plasma 
levels instead of genotypes. It is also important to consider that the populations of interest 
in these studies were patients with SLE, an autoimmune disease with a known increased risk 
for both arterial and venous thrombosis [251]. Another study examined the gene expression 
of various complement factors, including MBL, in peripheral blood mononuclear cells (PBMC) 
in patients with symptomatic PE and age- and sex-matched controls [252]. The MBL mRNA 
gene expression in PBMCs was lower in PE patients than controls. However, the study design 
was rated poor in a recent systematic review of the lectin pathway in thrombotic conditions 
due to a high estimated risk of bias [253]. The final study investigated the association 
between circulating MBL levels and VTE in a small case-control study conducted by our 
group [254]. We found that MBL deficiency (plasma levels <100 ng/mL) and low lectin 
pathway potential activity were associated with an increased risk of unprovoked VTE (OR 3.5 
and 2.7, respectively). A greater proportion of VTE patients (33.3%) had MBL-deficiency 
compared to age- and sex-matched controls (12.5%). As the study was small and 
underpowered, and the possibility of reverse causation could not be excluded, we 
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conducted the study in Paper II to examine the association between plasma MBL levels and 
risk of VTE in a larger population-based study with a prospective design. 
Several studies have suggested involvement of MBL and the lectin pathway in 
complement activation in response to hypoxic conditions [246, 249]. Hypoxia changes the 
protein expression [255] and glycosylation pattern [256] of endothelial cells [249]. These 
changes may explain why MBL binds to apoptotic cells [247, 248], as MBL usually does not 
bind to healthy host cells. Hypoxia characterizes the local environment in the venous 
valvular sinuses, where venous thrombi have been shown to originate, and it is likely to 
contribute to the pathological mechanism of VTE. The recognition of previously unexposed 
glycosylation patterns on host cells leads to binding of MBL and activation of the lectin 
pathway under these hypoxic conditions.  
The lectin pathway has been studied as a prothrombotic pathway. Several studies 
have investigated the role of MBL in arterial thrombosis. Indeed, in vivo animal studies 
suggest MBL and its associated serine proteases have a role in coagulation. Both MBL null 
and MASP-1/3 null mice show a prolonged bleeding time on tail tip excision [257]. The 
prolonged bleeding time in MBL null mice was reversed on reconstitution with recombinant 
human (rh)MBL. In the same study, the bleeding time in C3 null mice was similar to that of 
wild type controls, suggesting that the hemostatic problem occurred before the point of C3 
in complement activation and only involved components before the common pathway. A 
later study by the same group showed that both MBL null and MASP-1/3 null mice showed 
reduced FeCl3-induced thrombogenesis compared to wild type controls [258]. Reconstitution 
with rhMBL restored thrombogenesis to a similar degree as wild type mice. This study 
indicates that MBL and MASPs are both significant contributors to clot formation. 
Furthermore, in a model where mice expressed the human MBL2 gene, 3F8 monoclonal MBL 
inhibiting antibody prevented arterial thrombosis and limited myocardial injury in infarction 
[259]. The antibody 3F8 also prevented FeCl3-induced arterial thrombosis in the same MBL2-
expressing mice. Moreover, several studies have found that inhibiting the lectin pathway by 
using monoclonal antibody against MBL [260] or MBL knockout mice [261, 262] have 
decreased injury following myocardial ischemia-reperfusion. Recently, one research group 
proposed that MBL is a key factor in the pathogenic events following vascular ischemia in a 
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ischemic stroke model in mice, first by activating platelets and then by activating 
complement [263]. 
Though these animal studies have focused on arterial CVD, in vitro studies also 
support a prothrombotic role for MBL and the lectin pathway. Indeed, the MASPs are 
promiscuous proteins with thrombin-like substrate specificity in addition to their functions 
of cleaving complement components C2 and C4. MASP-1 can cleave fibrinogen and activate 
FXIII [264], high molecular weight kininogen (HMWK) [265], and TAFI [201]. Additionally, 
MASP-1 can activate PAR4 [266]. MASP-1 and -2 have both been shown to cleave 
prothrombin to thrombin [171, 172]. Thus, the prothrombotic potential of MBL and the 
MASPs should also be considered important in the development of venous thromboembolic 
disease.  
Overall, despite the clear role established by in vitro studies and animal studies, 
studies in humans show a somewhat inconsistent association between MBL levels and 
arterial CVD [253]. Some studies have found an association between low MBL genotypes or 
MBL deficiency and increased risk of atherosclerosis [267], carotid plaques [268], and 
myocardial infarction [269, 270]. These studies found that low MBL levels also predicted an 
earlier onset and more progressive disease [267]. As MBL-deficiency is also associated with 
susceptibility to infection, infection by Chlamydia pneumonia has been proposed as a link to 
the development of atherosclerosis [271, 272]. Other studies, however, found that high MBL 
genotypes or plasma levels were associated with an increased risk of acute coronary 
syndromes [273] and stroke [253, 274]. These studies also found high MBL levels were also 
associated with greater severity and a worse outcome [253, 274, 275], while individuals with 
MBL deficiency had smaller cerebral infarcts and a more favorable outcome [276, 277]. 
These discrepant results may be due to the different study designs and the populations 
examined in the studies.  
In order to eliminate the possibility that the risk estimates we found by plasma MBL 
were influenced by mediation of CVD, which increases the risk for VTE, we performed 
sensitivity analysis. Previous studies have found that CVD, such as ischemic stroke [107] and 
myocardial infarction [105], is a risk factor for VTE, especially within a short period 
immediately following the event. Therefore, we removed individuals who suffered a stroke 
or acute MI within 3 months prior to their VTE event from our analysis. We also excluded 
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patients with acute infections within 3 months before their VTE event, as low MBL may be a 
risk factor for infection, especially in early childhood [278, 279] or in adult patients with 
concomitant disease or immunodeficiency [280]. Acute infection is itself a risk factor for VTE, 
with the highest risk for an event occurring 3 months after infection [115]. Our sensitivity 
analysis gave results that were essentially similar to our overall findings, suggesting that the 
effects of plasma MBL levels were not affected by the presence of these comorbidities. 
Previous studies have shown that MBL-deficient individuals have a high prevalence of 
associated disease with increased susceptibility to various types of infectious disease as well 
as noninfectious disorders, including autoimmune disorders [176, 182, 183]. While MBL-
deficiency has been associated with the development of SLE and autoimmune disorders, we 
did not have data on these conditions and were thereby unable to do sensitivity testing on 
patients with these conditions. Autoimmune diseases such as SLE and rheumatoid arthritis 
are also known to be associated with increased risk of VTE [111, 251].  Nevertheless, our 
findings are not likely to be affected by the presence of individuals with these disorders, 
especially since we included CRP in our adjustment models. 
  Our findings in this study strengthen the evidence for a role for the complement 
system, and specifically the lectin pathway, in the development of VTE. At present, our 
findings are unchallenged and await confirmation by other studies. Future studies 
investigating the molecular mechanisms of the lectin pathway in the pathophysiology of VTE 
are warranted. 
 
5.2.3. ABO blood type, plasma mannose-binding lectin levels, and risk of venous 
thromboembolism (Paper III) 
In Paper II, we observed an association between plasma MBL levels and risk of VTE, with 
individuals with plasma MBL levels in the lowest quartile having a reduced OR for overall VTE 
(OR 0.79, 95%CI: 0.56-1.10) and DVT (OR 0.70, 95% CI: 0.47-1.04) compared to individuals 
with MBL levels in the highest quartile. This protective effect was even more pronounced 
(55% reduced risk) when restricting the time between blood sampling and VTE event to 4 
years. In Paper III, we set out to explore whether high plasma MBL levels were associated 
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with any genetic variants that could influence the association of high plasma MBL levels and 
risk of VTE. 
 Circulating MBL levels are largely genetically determined. Polymorphisms in exon 1 
and its associated promotor region of the MBL2 gene give varying levels of functional MBL 
[169]. The great variability in MBL levels even in individuals of the same haplotype suggests 
that there are still some undiscovered factors affecting circulating MBL levels [169]. We 
therefore performed a pQTL analysis to find genetic polymorphisms that are associated with 
high plasma levels of MBL. As high levels of MBL were associated with a greater risk, we 
looked for polymorphisms associated with the highest quartile of MBL levels. Among the 
SNPs that were significantly associated with high levels of MBL was a known polymorphism 
of the MBL2 gene (rs1800450). Unexpectedly, the rs8176719 SNP of the ABO gene, known to 
differentiate between O- and non-O blood types [64], was also significantly associated with 
high MBL levels. This association between blood type and MBL levels has not been 
previously described. 
 Non-O blood type is the most common risk factor for VTE [61, 281] with a population 
attributable risk of 20-30% [62, 282]. Many studies have found an association between blood 
type and risk of VTE, with non-O type individuals having the greatest risk (pooled OR 1.79, 
95%CI 1.56-2.05)[63]. The ABO gene has many polymorphisms that determine blood type, 
among which a homozygous deletion at the rs8176719 SNP site results in blood type O [64].  
 The mechanism by which there is an increased risk of VTE by non-O blood group is 
not fully understood, though it is partly attributable to vWF and Factor VIII. Non-O blood 
types have 25% higher levels of vWF and factor VIII compared to blood type O [65, 283]. This 
is similar to the 40% increased MBL levels in non-O blood types compared to type O blood 
we found in Paper III. Increased vWF levels are associated with an increased risk of VTE [66, 
284]. When adjusting for blood type, risk of VTE by both vWF [66, 285] and MBL levels 
(paper III) were attenuated. On the other hand, several studies have found that the risk of 
VTE by non-O blood type is not completely attenuated after adjusting for vWF and FVIII 
levels [66, 68] suggesting that non-O blood type has additional prothrombotic effects. 
Indeed, the ABO gene has been associated with many other proteins, many of which are also 
related to risk of VTE: galectin-3 [286, 287], P-selectin [288, 289], E-selectin [290-292], IL-6 
[293, 294] and ICAM-1 [288, 295]. Erythrocyte traits such as hematocrit, hemoglobin, and 
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red blood cell count that are associated with risk of VTE [296] are also associated with 
genetic variants of the ABO gene [286, 297, 298].  
 Unlike vWF which carries ABO blood group determinants [65], it has not been shown 
that MBL contains blood group moieties. Therefore, we created new subgroups of MBL 
levels and ABO blood type and examined the risk of VTE. We found that high levels of MBL in 
type O individuals still had increased risk of VTE, with OR estimates similar to risk by non-O 
blood type alone. Presumably this is not true for vWF, as vWF carries ABO blood type 
carbohydrates and thus likely has a different relationship with blood type than MBL.  
 High MBL levels gave the greatest risk of PE (OR 2.37), especially provoked PE (OR 
3.45), in individuals with O blood type. Our findings indicate that high MBL levels are an 
important risk factor for VTE in type O individuals. The risk of VTE by non-O groups remained 
similar regardless of MBL levels, with the exception of an attenuated risk for provoked PE in 
the high MBL/non-O blood group. Thus non-O blood type seemed to obscure the effect of 
high MBL levels. Whether MBL and the unknown effects of non-O blood type are part of the 
same prothrombotic mechanism or whether these two risk factors have separate effects 
that attenuate each other is not yet known.   
 As vWF is a highly glycosylated protein, it can also interact with several carbohydrate-
binding proteins such as lectins [299]. Indeed, the C-type lectin CLEC4M has been shown to 
bind and internalize vWF [300] and FVIII [301], thereby affecting plasma levels of these 
proteins. Two other C-type lectins, the macrophage galactose-type lectin (MGL) [302] and 
the Ashwell-Morrell Receptor (AMR) [303] were shown to be clearance receptors for 
hyposialylated vWF. Low density lipoprotein receptor-related protein 1 (LRP1) on 
macrophages has also been proposed as a mechanism of vWF clearance [304], and 
interestingly, a polymorphism of the receptor has also been associated with increased risk of 
VTE [305]. Notably, like vWF, MBL has also been found to interact with LRP1, both directly 
[306] or indirectly through calreticulin [247]. Galectin-1 and -3 have been shown to bind to 
vWF and possibly mediate thrombus formation through this interaction [307]. Whether MBL, 
a C-type lectin, can bind to or interact with vWF or whether these proteins share a common 




 The increased risk of VTE in individuals with high plasma MBL levels and type O blood 
was almost entirely limited to provoked events. Trauma, sepsis, and surgery are among 
provoking factors for VTE [308, 309], and complement activation is known to play a role in all 
of these conditions. High MBL levels may predispose to increased potential lectin pathway 
activity. Indeed, MBL levels have been found to correlate with potential lectin pathway 
activity in vitro [226, 254]. Lectin pathway activation occurring during provoking events may 
contribute to clot formation, especially given the pleiotropic effects of MASPs. The 
prothrombotic effects of MASP-1 include cleavage of fibrinogen to fibrin [264], prothrombin 
to thrombin [171], FXIII [264], TAFI [201], and HMWK [265],  and the activation of PAR4 
receptors [266]. These enzymatic effects are similar to that of thrombin. 
 The increased risk for PE by high MBL in type O individuals may be due to frequent 
embolization. Clots formed by MASP-1 have been shown to have thicker fibrin fibers and be 
less dense than clots prepared with thrombin [201], making them more susceptible to 
embolization. Alternately, although PE is often considered a sequel of DVT, up to half of 
cases find no concomitant DVT, suggesting that de novo formation of PE may occur locally in 
the lung vasculature [1]. In addition, recent studies have suggested they may have separate 
etiologies [57, 310].  
  The association of the non-O SNP with high levels of MBL is a novel finding, one 
which is complicated by the combined effects on risk of VTE. The risk of VTE is not additive 
when both factors are present. The association between high MBL and VTE appears more 
important in persons of type O blood, as persons of non-O blood type have a similarly 
increased risk regardless of MBL levels. Our hypothesis of increased lectin pathway activity 
and MASP-1 contribution to thrombus formation and embolization is plausible. Other 
studies are needed to confirm our findings. In the future, functional studies should examine 
possible mechanisms of MBL and the lectin pathway in the pathogenesis of VTE, and to 









- Complement activation, assessed by soluble terminal complement complex (TCC) 
levels, was associated with risk of incident venous thromboembolism, especially 
unprovoked events. Neither genome-wide nor complement-related genetic 
variants were significantly associated with plasma TCC levels, suggesting that 
predominantly environmental factors are involved in determination of plasma 
TCC levels.  
 
 
- Low plasma levels of mannose-binding lectin were associated with a decreased 
risk of venous thromboembolism, and especially deep vein thrombosis. The risk 
of VTE was not influenced by the presence of co-morbidities that are commonly 
associated with low MBL levels, such as arterial cardiovascular disease and 
infection, or cancer.  
 
 
- High plasma MBL levels were associated with an increased risk of VTE. The 
rs8176719 SNP determining O and non-O blood groups affected plasma MBL 
levels, and individuals with non-O blood type have on average 40% higher mean 
plasma MBL level compared to those with type O blood. High plasma MBL levels 
in type O individuals conferred an increased risk of VTE to a similar degree as non-






7. Final remarks and future perspectives 
The findings in this thesis support a role of the complement system in the pathogenesis of 
VTE. Overall complement activation, as measured by the TCC, was associated with risk of 
venous thromboembolism. Furthermore, the lectin pathway, investigated by plasma MBL 
levels, was also associated with VTE risk, and blood type. Our findings reveal a dynamic 
interaction between genetic determination of MBL and blood type, particularly in those with 
blood type O, as well as the environmental influence of overall complement activation, 
reflecting the interplay of many factors in this multicausal disease. 
 While the findings in this thesis suggest a role for complement in the pathogenesis of 
VTE, functional studies are needed to investigate the molecular mechanisms behind the 
associations. Future studies should validate our results, as well as investigate the effects of 
MBL and MASPs on thrombin generation in experimental studies. Similar studies on the 
other PRMs of the lectin pathway (ficolins and collectins) and on the MASPs are also 
warranted. 
  Our finding an association between circulating MBL levels and blood type is 
intriguing, and underscores the importance of an established yet still mysterious risk factor 
for thrombosis. Non-O blood group is associated with 25% higher vWF and FVIII levels [65, 
283], as well as 40% higher MBL levels in plasma. The increased risk for VTE conferred by this 
blood group remains after adjusting for these factors [66, 68], and the mechanisms for this 
remain unknown. More research is needed to elucidate possible mechanisms for the 
increased thrombotic risk by non-O blood groups. In vitro studies exploring possible 
interactions between vWF, FVIII, and MBL will be met with great interest.  
 Unravelling the mechanisms involved in the pathogenesis of venous thrombosis is 
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Background: It remains uncertain whether activation of the complement system, as‐
sessed by the soluble terminal C5b‐9 complement complex (plasma TCC), is associ‐
ated with future risk of incident venous thromboembolism (VTE).
Objectives: To investigate the association between plasma levels of TCC and future 
risk of incident VTE in a nested case‐control study, and to explore genetic variants 
associated with TCC using protein quantitative trait loci analysis of exome sequenc‐
ing data.
Methods: We sampled 415 VTE cases and 848 age‐ and sex‐matched controls from 
a population‐based cohort, the Tromsø study. Logistic regression models were used 
to calculate odds ratios with 95% confidence intervals for VTE across quartiles of 
plasma levels of TCC. Whole exome sequencing was conducted using the Agilent 
SureSelect 50 Mb capture kit.
Results: The risk of VTE increased across increasing quartiles of plasma TCC, particu‐
larly for unprovoked VTE. Participants with TCC in the highest quartile (>1.40 com‐
plement arbitrary units/mL) had an odds ratio for unprovoked VTE of 1.74 (95% 
confidence interval: 1.10–2.78) compared with those with TCC in the lowest quartile 
(≤0.80 complement arbitrary units/mL) in analyses adjusted for age, sex, and body 
mass index. A substantially higher risk for VTE was observed in samples taken shortly 
before VTE event. We found no association between genome‐wide or complement‐
related gene variants and plasma levels of TCC.
Conclusions: We found that high levels of plasma TCC were associated with VTE 
risk, and unprovoked events in particular. There was no genome‐wide association 
between gene variants and plasma levels of TCC.
K E Y W O R D S
complement system, protein quantitative trait loci analysis, terminal complement complex, 
venous thromboembolism, whole exome sequencing
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1  | INTRODUC TION
Venous thromboembolism (VTE) is a collective term for deep vein 
thrombosis (DVT) and pulmonary embolism (PE). VTE is a complex dis‐
ease, affecting 1–2 per 1000 individuals annually, with serious short‐ 
and long‐term complications, including recurrence and death.1,2 The 
incidence of VTE has slightly increased during the past two decades,3,4 
and it is likely that the incidence will continue to rise because the preva‐
lence of major risk factors for VTE, such as high age, obesity and cancer, 
are increasing in the population.5‒7 VTE has become a major challenge to 
public health and health care systems because of frequent hospitaliza‐
tions, monitoring of treatment to avoid bleeding complications, severe 
complications, and a high mortality rate after 30 days.8 It is therefore 
pivotal to identify novel biomarkers and unravel underlying disease 
mechanisms of VTE to facilitate targeted prevention and treatment.
The complement system is an important part of the innate immune 
system organized in a cascade of proteolytic serine proteases with a 
number of biological functions.9 Growing evidence from observational 
and animal studies suggests that the complement system is involved 
in the early steps of the pathogenesis of VTE, consistent with an ex‐
tensive cross‐talk between the complement and hemostatic systems.10 
Complement factor C3 is an acute‐phase reactant and a central compo‐
nent in activation of the complement system.11 In a large population‐
based cohort, subjects with plasma complement C3 levels in the highest 
tertile had a 58% higher risk of VTE than those in the lowest tertile; the 
risk estimate declined to 31% after further adjustment for C‐reactive 
protein (CRP) and body mass index (BMI).12 However, it is not known 
whether complement C3 is a marker or a mediator of VTE risk.
Activation of any of the three complement pathways merge at 
C3, which subsequently activates C5 and the terminal complement 
pathway, with final formation of C5a and the terminal C5b‐9 comple‐
ment complex (TCC).13 The TCC exists in two forms, surface‐bound 
C5b‐9 forming the membrane attack complex and a soluble form 
where C5b‐9 binds to vitronectin and clusterin and becomes non‐
lytic.14 Soluble TCC is generally accepted as a marker of in vivo com‐
plement activation and can be measured in plasma.15,16
No previous study has, to the best of our knowledge, investigated 
the association between plasma levels of TCC and future risk of VTE 
in individuals recruited from the general population. The aims of 
the present study were therefore to: (i) investigate whether plasma 
levels of TCC were associated with incident VTE in a nested case 
control study, (ii) explore whether genetic variants were associated 
with plasma levels of TCC using protein quantitative trait loci (pQTL) 
analysis of exome sequencing data; and (iii) investigate whether iden‐
tified gene variants (if present) were associated with risk of VTE.
2  | METHODS
2.1 | Study population
The Tromsø Study is a single‐center, population‐based cohort, with 
repeated health surveys of inhabitants of Tromsø, Norway. All 
inhabitants aged ≥25 years living in the municipality of Tromsø were 
invited to participate in the fourth survey, conducted in 1994–1995. 
A total of 27 158 subjects participated (77% of those invited), and 
were followed from the date of inclusion until an incident VTE, mi‐
gration, death, or end of follow‐up (September 1, 2007). All first 
lifetime VTE events were identified using the hospital discharge 
diagnosis registry and the autopsy registry and the radiology pro‐
cedure registry at the University Hospital of North Norway, which 
is the sole hospital in the Tromsø region. Trained personnel adju‐
dicated and recorded each VTE by extensive review of medical re‐
cords. A VTE was confirmed if presence of signs and symptoms of PE 
or DVT (proximal or distal) were combined with objective confirma‐
tion by radiological procedures (i.e., compression ultrasonography, 
venography, spiral computed tomography, perfusion‐ventilation 
scan, pulmonary angiography) or autopsy, and resulted in treatment 
initiation (unless contraindications were specified) as previously de‐
scribed.17 A VTE occurring in the presence of one or more provok‐
ing factors was classified as provoked. The following were regarded 
as provoking factors: surgery or trauma (within 8 weeks before the 
event), acute medical conditions (acute myocardial infarction, acute 
ischemic stroke, acute infections), immobilization (bed rest >3 days 
or confinement to wheelchair within the past 8 weeks) or other fac‐
tor specifically described as provoking by a physician in the medical 
record (e.g., intravascular catheter).
During the follow‐up period (1994–2007), 462 individuals ex‐
perienced a VTE event. For each case, two age‐ and sex‐matched 
controls, who were alive at the index date of the VTE event, were 
randomly sampled from the source cohort (n = 924). In total, 47 
cases and 76 controls did not have available plasma samples of suf‐
ficient quality for the analyses. Thus, our final nested case control 
study consisted of 415 cases and 848 controls.
2.2 | Baseline measurements
Height (to the nearest centimeter) and weight (to the nearest 0.5 kil‐
ograms) were measured in participants wearing light clothing and 
no shoes. BMI was calculated as weight divided by the square of 
height in meters. A self‐administered questionnaire was used to col‐
lect detailed baseline information on smoking status and previous 
Essentials
• It is unknown if terminal complement complex (TCC) is 
associated with venous thromboembolism (VTE).
• Genome‐wide and complement‐related gene variants 
were not associated with plasma levels of TCC.
• High plasma levels of TCC were associated with future 
risk of VTE, particularly unprovoked events.
• The association between plasma TCC and risk of VTE 
increased with shorter follow‐up time.
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cardiovascular events (stroke, angina pectoris, transient ischemic ac‐
cident, and myocardial infarction).
2.3 | Blood and DNA samples
Nonfasting blood was collected from an antecubital vein into 5‐mL 
vacutainers (Becton Dickinson, Meylan Cedex, France) containing 
ethylenediaminetetraacetic acid (K3‐ethylenediaminetetraacetic 
acid 40 μL, 0.37 mol/L per tube) as an anticoagulant. Platelet‐poor 
plasma was prepared by centrifugation at 3000 × g for 10 minutes at 
room temperature, after which the supernatant was transferred into 
cryovials (Greiner laboratechnik, Nürtringen, Germany) in 1‐mL ali‐
quots and stored at −80°C until further analysis. DNA isolated from 
blood was stored at the National CONOR Biobank.18
2.4 | Exome sequencing
Whole exome sequencing at high‐coverage (≈100×) was conducted 
in a subgroup of the study population (355 VTE patients and 354 
control subjects) using the Agilent SureSelect 50 Mb capture kit. The 
resulting genotypes were effectively filtered19 and imputations were 
carried out as previously described in detail.20
2.5 | Measurement of the soluble terminal 
complement complex
Plasma samples were thawed on crushed ice, and plasma levels of 
TCC were measured using an in‐house enzyme‐linked immuno‐
sorbent assay as described previously.15,21 In brief, enzyme‐linked 
immunosorbent assay plates (Nunc, Immunoplate II, Copenhagen, 
Denmark) were coated with the monoclonal antibody, aE11 specific 
for a neoantigen exposed in C9 after activation and incorporation 
into TCC, the poly (C9) unit of the TCC. Biotinylated anti‐C6 mono‐
clonal antibody (9C4) was used as detection antibody and strepta‐
vidin horseradish peroxidase (GE Healthcare UK) was added as 
the final step. Optical density was measured at 405 nm (Dynatech 
MR580; Dynatech Laboratories Inc., Alexandria, VA, USA). Results 
are given in complement arbitrary units (CAU)/mL. The intra‐assay 
coefficient of variation was negligible, and the inter‐assay coefficient 
of variation was 10.3%.15
2.6 | Statistical analysis
Statistical analyses were carried out using R, version 3.4.4 (The R 
Foundation for Statistical Computing, Institute for Statistics and 
Mathematics, Vienna, Austria). Plasma TCC was categorized accord‐
ing to quartile cutoffs in the control population (≤0.80, 0.80–1.04, 
1.04–1.40, >1.40 CAU/mL). Means and proportions of baseline char‐
acteristics across categories of TCC were calculated using descrip‐
tive statistics. Logistic regression models were used to calculate 
odds ratio (OR) for VTE with 95% confidence interval (CI) accord‐
ing to quartiles of TCC adjusted for age, sex, and BMI. We did not 
adjust for CRP because it is likely to be in the causal pathway of 
complement activation and VTE. The lowest quartile of TCC was 
used as the reference group. We also calculated the P value for linear 
trend of ORs across increasing quartiles of TCC.
Because the follow‐up time in the source cohort was long 
(≥12 years for many persons), the results based on baseline TCC 
measurements could be influenced by regression dilution bias.22 To 
investigate this, we performed analyses in which we restricted the 
maximum time from blood sampling in Tromsø 4 to the VTE events, 
while keeping all controls in the analyses. The logistic regression 
analyses on time restrictions were set to require at least 10 VTE 
events, and ORs were generated at every 0.1 year increase in time 
because blood sampling and plotted as a function of this maximum 
time.
The 1 034 910 genome‐wide variants derived from the whole‐
exome sequencing were used to investigate whether plasma TCC 
was regulated by any alternative genetic variants. This pQTL analysis 
was performed both in a genome‐wide setting, and restricted to the 
loci within ± 500 kb of the different genes involved in the comple‐
ment system (Table S1). To adjust for multiple testing, the commonly 
used significance threshold of 5 × 10−8 was used in the genome‐
wide setting. As the cis analysis in total contained 11 806 variants, 
a Bonferroni‐based adjustment for multiple testing corresponded to 
a significance threshold of 0.05/11.806 = 4.23 × 10−6. The plasma 
TCC values were transformed to follow a perfect standard normal 
distribution before entering the QTL analysis. The QTL analysis 
was done by the EPACTS (Efficient and Parallelizable Association 
Container Toolbox) software.23 The EMMAX (Efficient Mixed Model 
Association eXpedited)24 test within EPACTS was used, which uses 
a mixed model to test for associations between a quantitative trait 
(TCC in this study) and genetic variants while adjusting for covariates 
and genetic relatedness structure in the cohort.
3  | RESULTS
The distribution of baseline characteristics across quartiles of 
plasma TCC is shown in Table 1. The mean age, sex distribution, and 
mean BMI were essentially similar across quartiles of plasma TCC. 
The proportion of subjects with a history of cardiovascular disease 
was slightly lower and the proportion of smokers higher in the low‐
est TCC quartile. As expected, plasma levels of high‐sensitivity CRP 
increased across quartiles of TCC from 1.32 ± 1.08 mg/L in the low‐
est quartile to 1.96 ± 1.65 mg/L in the highest quartile.
The characteristics of the VTE patients are shown in Table 2. 
The mean age at the time of VTE was 67.4 years, and 48.4% of the 
cases were men. In total, 37.8% of the VTE events were PEs and 
62.2% were DVTs, and 42.2% of the cases were unprovoked. The 
most common provoking factors were surgery/trauma (22.4%) and 
active cancer (21.4%).
The ORs of VTE across quartiles of plasma TCC levels are 
shown in Table 3. For overall VTE, the OR increased across quar‐
tiles of plasma TCC (P for trend = 0.06), and subjects with plasma 
TCC > 1.40 CAU/mL had a 35% higher risk of VTE compared with 
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those with TCC ≤ 0.80 CAU/mL (OR: 1.35; 95% CI: 0.97–1.88). In sub‐
group analyses restricted to unprovoked VTE, the OR for the upper 
(>1.40 CAU/mL) vs. the lower quartile of plasma TCC (≤0.80 CAU/
mL) was 1.74 (95% CI: 1.10–2.78), and there was a statistically sig‐
nificant linear trend in the ORs across increasing quartiles of TCC 
(P for trend = 0.02). When restricting the analysis to provoked VTE, 
no difference in risk estimates of VTE across quartiles of TCC was 
observed. Further adjustment for BMI did not influence the esti‐
mates (Table 3). To consider the possibility of underestimating ORs 
resulting from regression dilution bias, we estimated ORs for VTE 
among subjects with high (highest quartile) vs. low (lowest quartile) 
plasma TCC as a function of time between blood sampling and the 
VTE events (Figure 1). The OR for VTE by high plasma TCC was sub‐
stantially higher with shortened time between the blood sampling 
and the VTE events.
The ORs for DVT and PE across quartiles of plasma TCC are 
shown in Table 4. The OR for DVT increased across quartiles of 
plasma TCC (P for trend = 0.06). Subjects with plasma TCC values 
>1.40 CAU/mL had a 38% higher risk of DVT compared with those 
with TCC ≤ 0.80 CAU/mL (OR: 1.38; 95% CI: 0.93–2.06). Although 
not statistically significant, the OR of unprovoked PE was higher 
in subjects with plasma TCC in the highest quartile compared with 
those in the lowest quartile (OR: 1.58; 95% CI: 0.82–3.10). The es‐
timates did not change after adjustment for BMI (Table 4). The ORs 
for DVT and PE among subjects with high (highest quartile) vs. low 
(lowest quartile) plasma TCC were calculated as a function of time 
between blood sampling and VTE (Figure 2). The ORs for DVT and 
PE showed essentially similar patterns as the ORs for overall VTE 
(Figure 1, left panel), and increased substantially with shortened 
time between blood sampling and the respective events.
To identify genetic variation associated with plasma levels of 
TCC, we tested for association between genome‐wide and comple‐
ment‐related variants and plasma levels of TCC. Figure 3 shows a 
modified Manhattan plot based on the results of the pQTL analy‐
sis with the genome‐wide variants marked by gray circles and the 
complement‐related analysis (variants within ±500 kb of the genes 
involved in the complement system) marked by blue triangles. Age, 
sex, BMI, and VTE status were included as covariates in the models. 
No gene variant had a P value that was statistically significant either 
in the genome‐wide or in the complement‐related analysis.
4  | DISCUSSION
We investigated the association between complement activa‐
tion, assessed by plasma levels of TCC, and future risk of VTE in 
a population‐based nested case control study. The risk of VTE in‐
creased across quartiles of plasma TCC, and subjects with plasma 
TCC >1.40 CAU/mL (highest quartile) had a 35% higher risk of overall 
VTE and 74% higher risk of unprovoked VTE compared with those 
with TCC ≤0.80 CAU/mL (lowest quartile). The ORs for VTE by 
plasma TCC increased substantially with shortened time between 
blood sampling and the VTE events. Further, we found no associa‐
tion between genome‐wide and complement‐related gene variants 
and plasma levels of TCC. Our findings indicate that plasma levels 
of TCC are independent of gene regulation, and that high levels of 
plasma TCC are associated with VTE risk, and unprovoked events in 
particular.
Few studies have investigated the link between complement 
factors and the risk of VTE. In a large population‐based cohort (the 
Plasma TCC (CAU/mL)




(n = 322) >1.40 (n = 331)
Age, years 58.7 ± 13.5 61.3 ± 12.8 61.4 ± 14.0 59.8 ± 14.4
Sex, % men (n) 50.8 (159) 48.1 (143) 42.2 (136) 48.0 (159)
BMI, kg/m2 26.3 ± 4.2 26.6 ± 4.0 26.2 ± 4.3 26.6 ± 4.4
hsCRP, mg/L 1.32 ± 1.08 1.50 ± 1.28 1.71 ± 1.30 1.96 ± 1.65
CVDa 13.7 (43) 17.5 (52) 16.1 (52) 15.1 (50)
Daily smoking 34.2 (107) 30.3 (90) 32.9 (106) 27.5 (91)
Note: aSelf‐reported history of cardiovascular disease (myocardial infarction, angina, stroke). 
TA B L E  1   Characteristics across 
quartiles of plasma levels of the terminal 
complement complex (TCC)
TA B L E  2   Characteristics of the venous thromboembolism (VTE) 
events (n = 415)
% (n)
Age at VTE, years 67.4 ± 13.6
Sex, male 48.4 (201)
Deep vein thrombosis 62.2 (258)
Proximal 72.5 (187)
Distal 27.5 (71)
Pulmonary embolism 37.8 (157)
Unprovoked VTE 42.2 (175)
Provoked VTE 57.8 (240)
Surgery/trauma 22.4 (93)
Active cancer 21.4 (89)
Acute medical condition 15.4 (64)
Immobilization 15.9 (66)
Estrogens 7.7 (32)
Other factor 3.9 (16)
938  |     HØILAND et AL.
Copenhagen General Population Study), 80 517 Danes were fol‐
lowed on average 4.9 years, in which 1176 developed VTE. Subjects 
with plasma complement C3 levels in the highest tertile had a 58% 
higher risk of VTE compared with those in lowest tertile, which de‐
clined to 31% higher risk of VTE after additional adjustment for 
CRP and BMI.12 Even though the risk estimate was attenuated by 
adjustment for CRP and BMI, the remaining risk and the pivotal 
role of complement C3,12 may suggest that complement C3 is not 
merely a marker, but a mediator of VTE risk. The latter concept is 
supported by experiments in C3‐ and C5‐deficient mice which had 
a lower incidence of VTE and reduced thrombus size compared to 
wild‐type mice in a tissue factor (TF)‐dependent model of flow re‐
striction‐induced VTE.25 Recently, we reported that high activity of 
the classical complement pathway was associated with unprovoked 
VTE in a small case control study.26 Furthermore, systemic lupus 
erythematosus (SLE) patients with a history of VTE had increased 
deposition of C1q, C3, and C4d on platelets compared with SLE 
patients without VTE, suggesting that activation of the classical 
pathway of the complement system may play a role in the patho‐
genesis of VTE in SLE patients.27 The authors speculated that the 
effect was mediated by formation of TCC at the surface membrane 
of platelets. Accordingly, we found that plasma TCC, the end stage 
of complement activation, measured in plasma was associated with 
increased risk of VTE, especially with unprovoked VTE. In contrast 
to plasma TCC and other activation products, which directly re‐
flect complement activation, plasma levels of individual comple‐
ment components such as C3 are not a reliable indicators of the 
degree of complement activation in vivo. Thus, our study strongly 
support the concept that the degree of complement activation, and 
not merely concentrations of parent molecules per se, is related to 
future risk of VTE.
Our study is, to the best of our knowledge, the first to provide 
actual evidence for an association between complement activation, 
assessed by plasma TCC, and future risk of VTE. In prospective stud‐
ies, the biomarker levels are usually measured at the time of inclu‐
sion and related to an outcome that occur several years later. Plasma 
levels of modifiable biomarkers are expected to change over time. 
Fluctuations in exposure during follow‐up will lead to a phenomenon 
called regression dilution bias,22 which results in an underestimation 
of the true association between exposure and outcome. Accordingly, 
we found that the risk of VTE by plasma levels of TCC declined sub‐
stantially with time between blood sampling and VTE.
In our study, genome‐wide and complement‐related gene vari‐
ants showed no association with plasma levels of TCC. These find‐
ings suggest that the plasma levels of TCC are mainly influenced by 
environmental rather than genetic factors. Autopsy and imaging 
studies indicate that venous thrombi originate in the valvular sinuses 
of large veins. The milieu in the valvular sinuses is characterized by 
Quartiles of plasma 
TCC (CAU/mL) Controls Cases Model 1 OR (95% CI) Model 2 OR (95% CI)
All VTE
≤0.80 220 93 Ref Ref
0.80–1.04 204 93 1.08 (0.76–1.53) 1.06 (0.75–1.51)
1.04–1.40 213 109 1.22 (0.87–1.71) 1.23 (0.88–1.73)
>1.40 211 120 1.35 (0.97–1.88) 1.33 (0.96–1.86)
P for trend 0.06 0.06
Per 1 SD increase 848 415 1.09 (0.97–1.22) 1.08 (0.97‐1.22)
Unprovoked VTE
≤0.80 220 35 Ref Ref
0.80–1.04 204 39 1.23 (0.75–2.02) 1.17 (0.71–1.94)
1.04–1.40 213 43 1.31 (0.81–2.15) 1.34 (0.82–2.19)
>1.40 211 58 1.74 (1.10–2.78) 1.72 (1.08–2.75)
P for trend 0.02 0.02
Per 1 SD increase 848 175 1.13 (0.99–1.29) 1.13 (0.99–1.29)
Provoked VTE
≤0.80 220 58 Ref Ref
0.80–1.04 204 54 0.99 (0.65–1.51) 0.98 (0.64–1.49)
1.04–1.40 213 66 1.17 (0.78–1.74) 1.15 (0.77–1.73)
>1.40 211 62 1.11 (0.74–1.67) 1.11 (0.74–1.67)
P for trend 0.47 0.47
Per 1 SD increase 848 240 1.03 (0.88–1.19) 1.04 (0.88–1.20)
Notes: Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex and body mass index.
TA B L E  3   Odds ratios (OR) with 95% 
confidence intervals (CI) for venous 
thromboembolism (VTE) according to 
quartiles of plasma levels of the terminal 
complement complex (TCC)
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severe hypoxia and stasis,28,29 conditions known to induce cellular 
immune responses. Because the complement system is activated by 
hypoxic cells and tissues,30 it is reasonable to assume that comple‐
ment is also activated in the hypoxic milieu in the valvular sinuses. 
It may be speculated that subjects susceptible to VTE exhibit a cer‐
tain pathophysiological milieu in the valvular sinuses, which makes 
them prone to complement activation and thereby development of 
VTE. Alternatively, other inflammatory conditions associated with 
increased plasma levels of TCC31,32 may be differentially distributed 
between subjects who will and will not develop VTE. However, be‐
cause the inflammatory response, in our study assessed by plasma 
CRP levels, secondary to such conditions would be in the causal 
pathway between plasma TCC and VTE risk, it would be method‐
ological incorrect to adjust for plasma CRP levels in the statistical 
analyses. In fact, complement activation is upstream of inflamma‐
tory responses such as CRP formation,33 but when CRP is produced 
and bound to surfaces it is able to activate the classical pathway of 
the complement system.34,35
A clear temporal sequence between exposure and outcome, 
such as in our nested case control study, is a prerequisite to estab‐
lish plasma levels of TCC as a risk factor of VTE. Circumstantial ev‐
idence support the concept that complement activation, assessed 
by plasma TCC, may be a mediator of VTE risk through platelet and 
coagulation activation because it reflects the degree of membrane‐
inserted C5b‐9. First, incorporation of the C5b‐9‐complex into the 
cell membrane activates platelets and results in (i) the exposure of 
negatively charged phosphatidylserine,36 which may assemble and 
amplify coagulation reactions37; (ii) the formation of procoagulant 
microvesicles,38 which is associated with risk of VTE39; and (iii) se‐
cretion of procoagulant granules from the cytoplasm of platelets.40 
Second, the complement system has direct procoagulant activities, 
including the ability to cleave and activate coagulation factors and 
increase TF expression in various cell types. In addition, C5a has the 
ability to upregulate the synthesis and release of plasminogen acti‐
vator inhibitor‐1, the main endogenous inhibitor of the fibrinolytic 
system, from mast cells and basophils,41 which further shifts the 
prothrombotic‐antithrombotic balance in favor of a prothrombotic 
condition.42
Strengths of our study include the recruitment of VTE patients 
from a population‐based cohort and age‐ and sex‐matched, ap‐
parently healthy controls from the same source population. It is 
a large prospective study, with robust measurements of plasma 
TCC. That blood samples were collected before VTE makes it 
possible to make assumptions on the direction of the associa‐
tion between exposure (complement activation) and outcome 
(VTE). Some limitations of the study need to be considered. The 
subgroup analyses of unprovoked/provoked PE and DVT were 
underpowered, and the results from these analyses should there‐
fore be interpreted with caution. The blood samples, in which the 
analysis of plasma TCC was conducted, were drawn in 1994–1995 
F I G U R E  1   Plots of estimated odds ratio (OR) for venous thromboembolism (VTE) as a function of time from blood sampling in Tromsø 4 
(1994–1995) and the VTE event (all, provoked, and unprovoked events) in analyses adjusted for age, sex, and body mass index. Large, solid 
circles indicate ORs with P values <0.05
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TA B L E  4   Odds ratios (OR) with 95% confidence intervals (CI) for deep vein thrombosis (DVT) and pulmonary embolism (PE) according to 
quartiles of plasma levels of the terminal complement complex (TCC)
Quartiles of plasma TCC 
(CAU/mL) Controls Cases Model 1 OR (95% CI) Model 2 OR (95% CI)
All DVT
≤0.80 220 56 Ref Ref
0.80–1.04 204 55 1.07 (0.70–1.62) 1.04 (0.68–1.58)
1.04–1.40 213 73 1.36 (0.91–2.02) 1.34 (0.90–2.00)
>1.40 211 74 1.38 (0.93–2.06) 1.36 (0.91–2.02)
P for trend 0.06 0.07
Per 1 SD increase 848 258 1.05 (0.90–1.20) 1.05 (0.90–1.21)
Unprovoked DVT
≤0.80 220 19 Ref Ref
0.80–1.04 204 22 1.28 (0.67–2.46) 1.22 (0.64–2.34)
1.04–1.40 213 28 1.58 (0.86–2.96) 1.59 (0.86–2.99)
>1.40 211 34 1.87 (1.05–3.45) 1.83 (1.02–3.38)
P for trend 0.03 0.03
Per 1 SD increase 848 103 1.05 (0.84–1.25) 1.06 (0.85–1.26)
Provoked DVT
≤0.80 220 37 Ref Ref
0.80–1.04 204 33 0.95 (0.57–1.59) 0.93 (0.56–1.55)
1.04–1.40 213 45 1.25 (0.78–2.02) 1.22 (0.75–1.97)
>1.40 211 40 1.12 (0.69–1.83) 1.12 (0.69–1.82)
P for trend 0.43 0.45
Per 1 SD increase 848 155 1.04 (0.86–1.22) 1.04 (0.86–1.22)
All PE
≤0.80 220 37 Ref Ref
0.80–1.04 204 38 1.10 (0.67–1.80) 1.07 (0.65–1.77)
1.04–1.40 213 36 1.01 (0.61–1.66) 1.04 (0.62–1.71)
>1.40 211 46 1.30 (0.81–2.09) 1.33 (0.82–2.15)
P for trend 0.35 0.28
Per 1 SD increase 848 157 1.12 (0.97–1.28) 1.12 (0.98–1.28)
Unprovoked PE
≤0.80 220 16 Ref Ref
0.80–1.04 204 17 1.16 (0.57–2.39) 1.10 (0.54–2.27)
1.04–1.40 213 15 0.99 (0.47–2.08) 1.00 (0.48–2.10)
>1.40 211 24 1.58 (0.82–3.10) 1.60 (0.83–3.15)
P for trend 0.23 0.20
Per 1 SD increase 848 72 1.19 (1.01–1.37) 1.19 (1.01–1.37)
Provoked PE
≤0.80 220 21 Ref Ref
0.80–1.04 204 21 1.05 (0.55–1.99) 1.02 (0.54–1.95)
1.04–1.40 213 21 1.01 (0.53–1.92) 1.03 (0.54–1.97)
>1.40 211 22 1.09 (0.58–2.05) 1.12 (0.59–2.11)
P for trend 0.83 0.74
Per 1 SD increase 848 85 1.02 (0.77–1.25) 1.03 (0.78–1.26)
Notes: Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, and body mass index.
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and stored at −80°C for up to 22 years. The long storage time 
could potentially affect the plasma levels of TCC; however, it is 
unlikely that this would change the results because this storage 
effect would be similar in all samples. Additionally, plasma TCC 
was only measured at baseline, and changes in TCC levels during 
follow‐up (up to 12 years) could result in underestimation of the 
true association.43 Accordingly, we found that the ORs for VTE by 
plasma TCC decreased substantially with prolonged time between 
F I G U R E  2   Plots of estimated odds ratio (OR) for deep vein thrombosis (DVT) and pulmonary embolism (PE) as a function of time from 
blood sampling in Tromsø 4 (1994–1995) and event in analyses adjusted for age, sex. and body mass index. Large, solid circles indicate ORs 
with P < 0.05
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F I G U R E  3   Modified Manhattan plot of quantitative trait loci analysis results. The upper, dashed horizontal line indicates the 5 × 108 
P value significance threshold. As the cis analysis has 11 806 variants being tested, a strict Bonferroni‐based control for multiple testing 
translates to a cis significance threshold of −log_10⁡0.00000423 = 5.37. This is indicated by the lower, dotted horizontal line in the figure. 
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blood sampling and the VTE events. Finally, plasma TCC is a very 
stable activation product compared with upstream activation 
products.21 Plasma levels of TCC remain unchanged after several 
freezing and thawing cycles 21 and storage at −70°C for 10 years 
(T.E Mollnes, unpublished data).
In conclusion, results from our nested case control study imply 
that complement activation, assessed by plasma levels of TCC, is as‐
sociated with increased risk of VTE, and unprovoked events in par‐
ticular. Genome‐wide and complement‐related gene variants were 
not associated with plasma levels of TCC, suggesting that local or 
systemic environmental factors are the dominating determinants of 
complement activation leading to increased plasma TCC. Functional 
studies are warranted to investigate the molecular mechanisms be‐
hind the association between plasma TCC and VTE risk.
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Study).	 Plasma	 MBL	 levels	 were	 measured	 using	 enzyme‐linked	 immunosorbent	
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1  | INTRODUC TION
Venous	thromboembolism	(VTE),	including	DVT	and	pulmonary	em‐
bolism,	affects	1	to	2	per	1000	 individuals	each	year.	 It	 is	a	major	
public	health	challenge	because	of	short‐term	and	 long‐term	com‐
plications,	 such	 as	 frequent	 recurrence	 and	 potentially	 death.1‒4 
Inherited	and	environmental	risk	factors	along	with	changes	in	blood	
flow,	hypercoagulability,	or	dysfunction	of	the	vessel	wall	affect	in‐



















may	suggest	 that	complement	C3	 is	a	mediator	 rather	 than	only	a	
marker	of	VTE	risk.




with	 serine	 proteases	 called	 MBL‐associated	 serine	 protease‐1,	
MBL‐associated	serine	protease‐2,	and	MBL‐associated	serine	pro‐
tease‐3	(MASPs‐1,‐2,‐3).14,15	The	MASP‐1	and	MASP‐2	are	activated	
when	MBL	binds	 to	 specific	 carbohydrate	 structures	 on	microbial	
and	cell	surfaces.	This	leads	to	cleavage	of	complement	factors	C4	
and	C2	 and	 the	 formation	 of	C4b2b	 convertase,	with	 subsequent	
activation	 of	C3	 and	 the	 common	 complement	 pathway.16 In vitro 
studies	have	shown	that	MASP‐1	has	thrombinlike	activity	and	can	
cleave	 factor	XIII	 (FXIII),	 fibrinogen,	 high‐molecular‐weight	 kinino‐
gen,	 and	 thrombin‐activatable	 fibrinolysis	 inhibitor,	while	MASP‐2	
can	 cleave	prothrombin	 to	 thrombin.15,17	The	MASPs	 can	 activate	




spite	 a	 moderate	 increase	 during	 an	 acute‐phase	 response.21,22 
The	MBL	levels	vary	markedly	between	individuals	because	of	the	







protect	 against	 development	 of	 VTE.	 However,	 in	 patients	 with	
systemic	 lupus	 erythematosus,	MBL2‐deficient	 genotypes	 were	
associated	with	increased28	or	unchanged29	risk	of	VTE,	whereas	
low	 plasma	 levels	 of	 MBL	 (<100	 ng/mL)	 were	 associated	 with	
increased	 VTE	 risk	 in	 a	 small	 case‐control	 study	 recruited	 from	
the	 general	 population.30	 The	 conflicting	 results	 may	 partly	 be	
explained	 by	 chance	 because	 of	 the	 low	number	 of	 participants	
included	 in	 these	 studies,	 inconsistent	 patient	 selections,	 or	 the	
retrospective	 nature	 of	 the	 case‐control	 study	 with	 the	 poten‐




Conclusions: Our	 findings	suggest	 that	 low	plasma	MBL	 levels	are	associated	with	
reduced	risk	of	VTE,	and	DVT	in	particular.










•	 The	 OR	 for	 VTE	 decreased	 with	 decreasing	 time	 be‐
tween	blood	sampling	and	event.






The	 Tromsø	 Study	 is	 a	 single‐center,	 population‐based	 cohort,	

















jective	 confirmation	 by	 radiological	 procedures,	 which	 resulted	 in	
initiation	of	 treatment	 (unless	 contraindications	were	 specified).	A	
VTE	occurring	in	the	presence	of	one	or	more	provoking	factors	was	
classified	 as	 provoked.	 Provoking	 factors	were	 surgery	 or	 trauma	
(within	8	weeks	before	 the	 event),	 acute	medical	 condition	 (acute	

















Body	 mass	 index	 (BMI)	 was	 calculated	 as	 weight	 divided	 by	 the	
square	 of	 height	 in	meters	 (kg/m2).	 A	 self‐administered	 question‐
naire	was	used	to	collect	a	detailed	history	of	previous	cardiovascular	
disease	(CVD)	events	(stroke,	angina	pectoris,	transient	ischemic	at‐
tack,	 and	myocardial	 infarction),	 recurrent	 VTE,	 diabetes	mellitus,	
and	 other	 concurrent	 diseases.	 The	 questionnaire	 also	 included	
questions	about	dietary	habits,	physical	exercise,	 smoking,	and	al‐
cohol	consumption.
2.3 | Blood sample collection and storage of 
blood products
At	 inclusion	 in	 Tromsø	 4	 (1994‐1995),	 non‐fasting	 blood	 was	 col‐
lected	 from	 an	 antecubital	 vein	 into	 5‐mL	 vacutainers	 (Becton	








at 13 000 g	to	obtain	platelet‐freeplasma.









intraindividual	 and	 interindividual	 coefficients	 of	 variation	 were	














culated the P	 value	 for	 linear	 trend	 across	 decreasing	quartiles	 of	
MBL.	Separate	analyses	were	also	conducted	with	unprovoked	VTE,	
DVT,	and	PE	as	the	outcomes.
The	 results	 were	 based	 on	 a	 single	 baseline	 measurement	
with	 long	 follow‐up	 (>12	years	 for	many	 individuals)	 and	 could	be	
4  |     LIANG et AL.

















































Q2 (435-1367  
ng/mL)




n 310 320 311 325
Age	(years) 62	±	13 60	±	13 61	±	14 59	±	15
Sex,	%	men	(n) 44.5	(138) 45.6	(146) 43.7	(136) 54.7	(178)
BMI,	kg/m2 26.8	±	4.3 26.7	±	4.4 26.7	±	4.3 25.4	±	3.8
Smoking,	%	(n) 28.7	(89) 28.4	(91) 28.3	(88) 38.8	(126)
hsCRP,	mg/L 1.71	±	1.5 1.67	±	1.4 1.50	±	1.2 1.63	±	1.4
CVDa,	%	(n) 16.1	(50) 13.1	(42) 18.0	(56) 16.3	(53)
Cancerb,	%	(n) 3.1	(10) 6.8	(21) 4.4	(14) 3.9	(12)






TA B L E  1  Distribution	of	baseline	
characteristics	according	to	quartiles	of	
plasma	levels	of	MBL























in	 participants	 without	 cancer	 (Table	 S1)	 and	 without	 those	 who	
developed	myocardial	 infarction	 or	 stroke	 or	 had	 acute	 infections	







































Quartiles of MBL (ng/mL) Controls Cases
Model 1 Model 2
OR (95% CI) OR (95% CI)
Overall	VTE
≥2423 212 113 Reference Reference
1368‐2422 213 98 0.87	(0.62‐1.21) 0.81	(0.58‐1.13)
435‐1367 212 108 0.96	(0.69‐1.33) 0.88	(0.63‐1.22)
<435 212 98 0.87	(0.62‐1.21) 0.79	(0.56‐1.10)
P	for	trend 0.6 0.2
DVT
≥2423 212 75 Reference Reference
1368‐2422 213 63 0.84	(0.57‐1.23) 0.79	(0.53‐1.17)
435‐1367 212 65 0.87	(0.59‐1.27) 0.80	(0.54‐1.18)
<435 212 57 0.76	(0.51‐1.13) 0.70	(0.47‐1.04)
P	for	trend 0.2 0.1
PE
≥2423 212 38 Reference Reference
1368‐2422 213 35 0.92	(0.56‐1.52) 0.85	(0.51‐1.41)
435‐1367 212 43 1.14	(0.71‐1.84) 1.04	(0.64‐1.69)





















complications.	 Systemic	 lupus	 erythematosus40	 and	 acute	 infectious	
diseases41	are	associated	with	increased	risk	of	VTE	and	may	therefore	





















pathway	 to	 thrombogenesis.15,17‒19,44	 Both	 MASP‐1	 and	 MASP‐2	





a	 receptor	 responsible	 for	 the	 activation	 and	 aggregation	of	 plate‐
lets	as	well	as	proinflammatory	processes	such	as	leukocyte	recruit‐











thrombus	formation	both	 in vitro and in vivo	 in	a	mouse	thrombosis	
Quartiles of MBL 
(ng/mL) Controls Cases
Model 1 Model 2
OR (95% CI) OR (95% CI)
Unprovoked	VTE
≥2423 212 46 Reference Reference
1368‐2422 213 42 0.93	(0.59‐1.47) 0.85	(0.53‐1.36)
435‐1367 212 47 1.04	(0.66‐1.63) 0.94	(0.60‐1.49)
<435 212 41 0.92	(0.58‐1.46) 0.80	(0.50‐1.29)
P	for	trend 0.9 0.5
Unprovoked	DVT
≥2423 212 28 Ref Ref
1368‐2422 213 29 1.05	(0.60‐1.84) 0.98	(0.55‐1.72)
435‐1367 212 26 0.95	(0.53‐1.67) 0.86	(0.48‐1.53)
<435 212 21 0.78	(0.43‐1.42) 0.67	(0.36‐1.24)
P	for	trend 0.4 0.2
Unprovoked	PE
≥2423 212 18 Ref Ref
1368‐2422 213 13 0.74	(0.35‐1.54) 0.68	(0.32‐1.43)
435‐1367 212 21 1.19	(0.62‐2.30) 1.09	(0.56‐2.12)























be	associated	with	VTE	risk40,41,56,57 and could thereby counterbal‐
ance	the	potential	beneficial	effect	of	MBL	deficiency.	Mannose‐
binding	 lectin	 deficiency	 has	 been	 associated	 with	 advanced	
atherosclerosis58,59	 and	a	higher	 risk	of	myocardial	 infarction,	 in‐








matched	controls	 from	the	same	source	population.	 It	 is	a	 large	
prospective	 study	 where	 blood	 samples	 were	 collected	 before	
VTE,	 allowing	 assumptions	 on	 the	 direction	 of	 the	 association	
between	 exposure	 (plasma	 levels	 of	 MBL)	 and	 outcome	 (VTE).	
The	 blood	 samples	 used	 for	 plasma	 MBL	 analysis	 were	 drawn	
in	1994‐1995	and	stored	at	−80°C	 for	up	 to	22	years.	The	 long	
storage	 time	 could	 potentially	 affect	 the	 plasma	 levels	 of	MBL.	
However,	 it	 is	 unlikely	 that	 it	 would	 affect	 the	 results,	 as	 the	
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F I G U R E  1  Plots	of	estimated	ORs	for	overall	VTE,	DVT,	and	PE	as	a	function	of	time	from	blood	sampling	in	the	fourth	survey	of	the	
Tromsø	Study	(1994‐1995)	and	event	in	analyses	adjusted	for	age,	sex,	BMI,	and	hsCRP.	Large,	solid	circles	indicate	ORs	with	P	values	<	0.05.	
CI,	confidence	interval;	DVT,	deep	vein	thrombosis;	OR,	odds	ratio;	PE,	pulmonary	embolism;	VTE,	venous	thromboembolism
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